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ABSTRACT

A combined effect o f sonication and layer-by-layer assembly (LbL) enhances the
solubility o f many poorly soluble inorganic and organic materials by forming stable
particles with ca. 200 nm size and up to 90 wt% o f loading. The entire method is
reproducible, easy-to-handle, and flexible for varying surface properties according to the
application o f the materials. The method develops good colloidal stability o f materials in
buffers and maintains architecture for future improvement. A top-down approach, with a
combined effect o f sonication and LbL assembly, ruptures the material and allows
adsorption o f oppositely charged polyelectrolytes simultaneously. Thus, the approach is
applicable for low solubility anticancer drugs, dye pigments, anticorrosion agents, salts,
and oxides. In comparison, the well-established bottom-up approach begins with the drug
dissolved in an organic solvent. The nanoparticles precipitate from the solution through
nucleation initiated by the addition o f an aqueous polyelectrolyte solution under
sonication. This process produces low solubility anticancer drugs nanoparticles ca. 200
nm with 30% o f the yield.
Advancement o f the bottom-up approach for paclitaxel formulation begins by
addition o f amphiphiles and pharmaceutical excipients during the drug nucleation
process, which indirectly improves the shelf-life o f the drug formulation. The
amphiphiles adsorb onto the hydrophobic surface o f the drug and play a dual role of
decreasing recrystallization and acting as anchors to the multilayers o f

polycation/polyanion during LbL assembly. Incorporation o f polyethylene glycol (PEG)
moieties in LbL assembly improves further colloidal stability, as compared to the nonPEG shell composition. The nanoparticle diameters reduce to 160-180 nm, with 80 wt%
loading capacity and concentration o f 2-3 mg/mL. Varying the number o f multilayers of
the shell composition leads to controlled paclitaxel release rates, which can be extended
for

1 0 -2 0

hours.

To improve the nanoparticle circulation time, the particle surface is modified by
excess PEG moieties. Indirectly, the surface properties o f the particles advance by
restricting serum protein adsorption. In vitro studies using the 4T1 cancer cell line help to
direct further modification o f the nanoparticle surface. The safety and tolerability o f all
constituents in the formulation are confirmed in mice via tail vein administration. The
LbL shell architecture is developed further for anchoring tumor specific monoloclonal
antibodies, 2C5. Here we report on the successful architecture o f paclitaxel nanoparticles
based upon PEG integrated LbL shell composition and conjugation o f tumor specific
biomolecules for longer circulation time as well as targeted delivery.
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CHAPTER 1

INTRODUCTION

1.1

Motivation

The American Cancer Society estimated that the deaths o f 577,190 people in the
United States were due to various cancers during the year 2012. A projected figure for
new cancer cases o f 1,638,910 will add to the existing numbers in the current year [1].
Several treatments including surgery, chemotherapy, radiation, hormonal therapy, cancer
immunotherapy, and targeted therapy, have been carried out for cancer treatment with
partial success. But, elimination o f the entire tumor remains a challenge for researchers.
Based on previous studies, 40% o f the newly developed effective drugs will be poorly
soluble in water [2]. Among the various cancer treatments, our work is focused to
develop targeted therapy o f poorly soluble drugs. For cancer treatments, novel
compounds from natural as well as synthetic sources have been proven to eradicate
tumors. The formulation o f water-soluble compounds is comparatively easier compared
to poorly soluble drugs. Most effective drugs with hydrophobic or polycyclic nature (less
soluble) often bring challenges to attain the desired properties for effective cancer
treatment. Previous attempts to use such poorly soluble drug formulations adversely
affected normal cells. One way to solve this problem is to prepare stable nanocolloids of
the drug and conjugate with ligands to achieve sustained release as well as targeted
delivery. We hypothesize that ultrasonication assisted LbL assembly will help to form

1

2
nanoparticles with great repulsion among particles to avoid aggregation. The details o f
this concept are described below.

1.2

Research Goals

In this work, nanoparticles of a poorly soluble anticancer drug, paclitaxel, will be
developed according to the following method on a step by step basis:
1)

Development stable nanocolloids using sonicaton assisted LbL assembly

(SLbL): In the beginning, SLbL will be developed on synthetic polyelectrolytes,
including polystyrene sulfonate (PSS) as a polyanion and polyallylamine hydrochloride
(PAH), as a polycation. Due to the characteristic high charges o f synthetic
polyelectrolytes, the method will become easy-to-handle and will help to maintain stable
nanocolloids for a long time with a drug loading efficiency o f up to 90% wt. Another
important task is to obtain particle diameters o f less than
2)

200

nm.

Establish nanoencapsulation shell using biological-sourced poly electrolytes:

Aiming towards nanoparticles for intravenous administration, SLbL will be shifted from
synthetic polyelectrolytes to biological-sourced polyelectrolytes. A few examples of
biological sourced polyelectrolytes include chitosan, poly-l-lysine, heparin, alginic acid,
dextran sulfate and bovine serum albumin (BSA). This task will be a step towards the
improvement o f biodegradability issues and high concentration o f up to 2-3 mg/mL o f the
nanoparticles, in addition to particle size and loading efficiency.
3)

Characterization o f nanoparticles: Physico-chemical properties o f the

nanoparticles will be confirmed using scanning electron microscopy (SEM) as well as
hydrodynamic ^-potential measurements. The stability o f nanoparticles needs to be
attained for better shelf-life (more than two weeks). At this point, several attempts at drug

nanoparticles preparation will be carried out for establishing a reliable method in terms of
obtaining particle size below 200 nm and drug load up to 90 wt%.
4)

Improvement of the LbL shell to meet the required drug release rate and

long circulation time: To analyze the controllable rate o f drug release at sink conditions
(between 6 and 24 hours), a set of samples will be prepared to apply 2-3 different
polycation/polyanion pairs with one to four bilayer coats for each pair to control their
stability and drug release rate [3]. The drug release kinetics will help to obtain
preliminary information for the drug formulation in future clinical development. In
addition, QCM studies will help to design the shell composition for longer circulation
time.
5)

Development of targeted nanoparticles: Based upon previous work on

liposomal carriers, we will optimize the amount o f polyethylene glycol in the outermost
layer o f the LbL shell. The nanoparticles of poorly soluble drugs with desired bilayers
which protrude through outer layer with reactive groups (NH 3 + or COO ) will be used to
attach polyethylene glycol (PEG) and/or antinucleosome monoclonal antibody 2C5. For
targeted delivery, PEG as the “outermost” layer along with cancer specific
antinucleosome monoclonal antibody 2C5 will help to increase circulation time of
nanoparticles in the blood stream and achieve the required bioavailability at the tumor
site. The cytotoxicity o f non-targeted and targeted LbL-coated drug nanoparticles on a
breast cancer cell line of 4T1 will be assessed.

1.3

Outline o f the Dissertation

This dissertation includes six chapters. Chapter 2 describes background
information o f layer-by-layer assembly, its application in various biomedical fields

4
including special accounts on drug delivery systems (DDS). The progress o f DDS during
the past three decades is discussed in the context o f the present work. Chapter 3 includes
details o f instruments which are commonly used for the entire work. In addition, the
related materials and methods are described at the beginning of further chapters as
needed.
In Chapter 4, the top-down approach of sonication-assisted layer-by-layer
assembly is applied for a wide range of poorly soluble materials, which are classified as
organic and inorganic compounds. This method allowed for the nanoparticulation of lowsoluble anticancer drugs, anticorrosion agents, MRI contrast improving agent, insoluble
dyes, and inorganic salts. The entire method of preparation is developed without any
additives, surfactants, and emulsifiers. Aiming to develop paclitaxel as an example of
anticancer drug formulation, we compared “top-down” and “bottom-up” approaches in
terms o f particle size, release rate, and yield of the final product. Chapter 5 briefly
describes the limitations o f the method in the previous chapter. A detailed description is
given o f a new architectural approach to prepare hydrophobic paclitaxel nanocores in the
presence o f amphiphilic or polymeric surfactants followed by deposition o f thin
multilayer shells o f PEGylated polycations/polyanions using washless LbL assembly.
The effect o f each constituent (surfactants and excipients) on the nanoparticle preparation
is described for the improvement o f existing methods. The importance o f PEG-modified
polyelectrolytes is analyzed in order to improve the colloidal stability of the dispersions
and attain some protein-resistant properties. Chapter 6 describes development of
paclitaxel nanoparticles for targeted delivery by conjugating 2C5 monoclonal antibodies.
The samples from the previous chapter are studied for cell culture and in vivo studies in
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mice. Finally, Chapter 7 describes the accomplishments o f the entire work and remarks
on future studies.

CHAPTER 2

BACKGROUND

2.1

Background Information

Aiming for development o f anticancer drugs formulation, we prepared the
nanoparticles o f low solublity anticancer drugs by combining LbL assembly and
ultrasonication. A detailed review of the development o f LbL assembly and its
biomedical applications, including drug delivery system is given as below. Since the
work is focused towards nanoparticulation o f paclitaxel as an example o f an anticancer
drug, we discussed several involving about research in drug delivery methods and the
existing commercial formulations of paclitaxel.

2.2

Layer-by-layer Assembly

In 1993, layer-by-layer assembly was introduced as a well-established technique
for generating thin films for applications in several fields such as, tissue engineering,
pharmaceutical, biosensing and biomimetics research. LbL assembly is the deposition of
alternative charged polyelectrolytes to form controllable nanometer-scale layers on any
surface. Oppositely charged polyelectrolytes interact through electrostatic interactions
and ionic bonds (Figure 2.1). The interaction between polyelectrolytes also depends on
the polymer charge. In other words, the longer the chain o f monomers, the stronger will
be the overall charge on the particular polyelectrolytes [4,5].

The traditional dipping method o f LbL assembly is quite slow, even when
automated, and it is also irregular for a manual process. Thereafter, several approaches
were evolved to accelerate the LbL process by a spin assembly technique. By using
spraying, LbL can process large areas with very short contact time and skips the washing
steps that are needed in the dipping method.

Figure 2.1: Sequential adsorption o f alternative charged polycation (red) and polyanion
(blue) on a solid surface
The most fascinating feature o f LbL is the encapsulation or introduction of the
biologically active materials in LbL films by maintaining their biological properties.
Since each layer o f the LbL assembly is formed a nanolayer at a time, the entire process
can be controlled with high precision at the nanometer scale [6,7]. The variation o f shell
composition could be done by coating synthetic and natural polyelectrolytes, proteins,
lipids, inorganic and organic nanoparticles. Such variation in components of the shell
provides versatile properties including particle size, controlled dissolution rate o f loaded
materials, and desired constituents o f shell composition [7-11]. LbL assembly on a solid
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surface has been well established as a technique to form a thin film for biomedical
applications in biosensing, tissue engineering, and regenerative medicines. A few
examples include biocompability coating for implantable biomedical devices, such as
stents, one-shot or programmed delivery o f DNA, sequential delivery o f drugs, wound
healings in arteries, and development o f physico-chemical features o f multilayer module
for cell adhesion, proliferation, and differentiation [ 1 2 ].
2.2.1

LBL Applications for Development of Delivery Carriers
A group o f researchers carried out drug diffusion using the LbL dipping method

based upon multilayers o f synthetic polyelectrolytes. The structural features of the
multilayers were modified to understand its application in drug release kinetics. In
general, microporous multilayers were found to provide comparatively faster drug
diffusion as compared to the corresponding nonporous films. In the conclusion, the drug
release rate o f multilayers was found to be dependent on the pore size in the films and the
number o f layers [13].
2.2.2

Microcapsule as Drue Delivery
Polyelectrolyte capsules can be used as a delivery tool by two methods. First, the

encapsulated material forms a template core which is followed by LbL assembly. Second,
the macromolecules can be incorporated in the multilayered shell [14-16]. LbL assembly
o f nanometer-thick polymeric layers can be developed on the surface o f micron-sized
decomposable cores, such as polystyrene, melamine formaldehyde (MF), carbonates
(CaCC>3 and MnCCh), and silica. After LbL assembly, the cores can be dissolved by
using hydrochloric acid, teteahydrofluran, hydrogen fluoride, and ethylene diamine
tetraacetic acid (EDTA), respectively. Based on the previous method, “hollow” capsules
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were used as a carrier for various biomolecules, such as low molecular weight drugs,
polymers, enzymes, DNA, and proteins (Figure 2.2). The encapsulation efficiency o f
biomolecules in the capsules depends on the number o f bilayers and the molecular weight
o f the biomolecules [17-20].

polycation

Iwiic,u3cores

LbL assembly of polycation/ macromolecules
0.1 M
EDTA.pH
7.0 or 5.0

Hollow microcapsule

I

removal of core

Figure 2.2: Schematic representation o f hollow microcapsules as carriers for the delivery
of macromolecules
Other than the core dissolving method, various strategies have been reported for
as the opening/closing system for LbL microcapsules. Common controlling mechanisms
involved variation in pH, solvent mixture and dielectric switching [21,22]. Another
interesting work for development o f drug delivery systems includes the analysis of the
interaction between specific drug and functional groups in microgel. The study showed
the optimized conditions o f microgel morphology for drug uptake and release
applications depending on the target drug [23].
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Fabrication o f nanoparticles by electrostatic interaction o f polylectrolyte
complexes was developed using a combination o f alginic acid and chitosan. This specific
combination was applicable towards the delivery o f protein and peptide drugs [24,25].
Whereas, self-assembled natural polymers, such as alginic acid and pectin separately,
with Ca

2+

i

and CO ' ions under mild conditions was developed for improved drug release

properties, such as low molecular weight anticancer drugs. So the natural polymers are
advantageous in comparison to synthetic material in terms o f biocompability, less toxicity
and controllable release properties [26,27],
A similar method to the described approach of sonicated LbL encapsulated was
applied to form micron size bubbles containing hydrophobic dyes with polyglutomate as
interface macromolecules [28]. Poor water soluble molecules also may be driven into
LbL microparticles and precipitate there by adjustment o f polarity or pH gradient [29].
LbL coated submicron size methoxyestradiol crystals were also produced [30]. All these
works have shown a good degree o f success but they are lacking a generality and
formulated particles were o f much larger diameter.
2.2.3

Microcapsules for In Vitro Study
A key feature o f a multilayered shell is to load biomolecules, such as enzymes,

peptides, and DNA as well as synthetic materials including drugs and dyes. The
multilayered shell can preserve the bioavailability and functionality o f aforementioned
materials in biological buffers. The interaction o f a micron-sized LbL multilayered shell
with MCF-7 breast cancer cells was investigated to understand the implications o f a
different outermost layer, such as cationic polymers, anionic polymers, lipid bilayers, and
an outermost layer with different electrostatic potentials. The multilayered shell surface
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was found to have a higher absorption affinity towards albumins, globulins, and
fibrinogen. Both albumins and fibrinogen predominantly adsorbed on cationic films as
compared to anionic films. The adsorption o f proteins on the LbL shell surface changed
not only the surface potential, but also cell uptake. The multilayered shell showed less
cell uptake with albumin adsorbed on the particle surface and vice versa. The protein
adsorption can be reduced by coating the multilayered shell with polyethylene glycolgrafted polymers. The amount o f copolymer needs to be optimized for less protein
adsorption by choosing an optimal PEG grafting ratio. By understanding the role o f
micron sized particles for better cell uptake, we developed a PEGylated nanometer sized
multifunctional shell as an anticancer drug delivery system [31].

2.3

Nanometer Sized Drug Carriers

Nanoparticles-based drug delivery systems have advantages over traditional
therapies, such as targeted delivery o f high-loading capacities o f multiple drugs and
overcoming cellular surface multiple-drug resistance mechanisms. In particular,
nanometer-sized drug delivery systems have been extensively studied for cancer
treatment and various infectious diseases, which include liposomes, vesicles, polymer
micelles, and polymerosomes. In the past decade, tremendous work has been focused to
develop nanoparticles through the LbL assembly method for biomedical applications.
The LbL assembly is a highly versatile method for developing particles of different size,
shape, and composition. Among LbL assembly with different surface functionalized
molecules, PEG coated particles were found to be increasing the circulation time as well
as enhancing tumor retention of the nanoparticles [32].
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Nanoscale drug carriers for tumor targeting can work through active or passive
targeting. The passive targeting mechanism o f the nanoparticles was analyzed to enhance
the circulation time due to the outermost hydrophilic layer with PEGylated molecules to
avoid immune response. Active targeting is a step ahead o f passive targeting and involves
the nanoparticles conjugated with active biomolecules, example antibodies, against the
specific ligand o f the cancer cells [33]. The targeting moieties not only improve
nanoparticle uptake by cancer cells but also increase their residence time in the tumor. A
common approach to attain tumor selectivity involves binding specific ligands to the LbL
coated nanoparticles that are specific for cancer cells [34].
2.3.1

Micelles. Vesicles, and Liposomes
Micelles and vesicles are commonly studied nanosized drug carriers [35]. The

preparation o f polymeric micelles is limited to specific organic solvents. The inclusion of
an organic solvent may cause a reduction in bioactivity o f some drug [36].
Liposomes are another major class o f drug delivery systems involving selfassembly o f lipids. Liposomes excel over other drug delivery systems in terms of
protecting drugs from degradation, have less toxicity, and are easier for conjugating
targeted biomolecules. Liposomes have few limitations including preparation based upon
less stability in an in vivo study and low drug loading capacity [37,38].
Intravenous administration o f liposomes has been applied to maintain prolonged
circulation time o f a drug. The repulsion barrier between two close proximity particles
can be avoided by adsorbing nonionic surfactants onto the outside surface. The presence
o f surfactants diminishes Van der Waals forces between particles [39-41]. To suppress
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immune response towards liposomes, the surface conformation was modified using PEG
molecules in addition to surfactants, like poloxamer and poloxamine[42].
Doxil® is a commercial product o f doxorubicin, which has coated with
PEGylated liposomes. Still, the PEGylated surface could not sufficiently resist the
complement-based opsonization process [43]. Tests o f nanoparticles coated with PEG
molecules o f different molecular weight demonstrated that 20 kDa PEG molecules
optimally reduced complement activation [42], In addition, negatively charged surface
liposomes were implicated to activate the complement system [44-46]. Altogether several
features o f liposomes, such as surface charge and composition, help to develop
prospective drug delivery systems for better circulation time.
2.3.2

Nanocapsule. Nanospheres and Nanoparticles
Several studies showed the advantages o f nanometer sized carriers over

conventional drug delivery systems in terms o f drug efficacy. Depending on the method
o f preparation, such nanometer-scale carriers can be classified as, nanocapsules,
nanospheres, or nanoparticles. Nanocapsules confine the drug to a core surrounded by a
unique polymer membrane, whereas nanospheres contain the matrix system with a
uniform dispersion o f the drug. In general, nanoaprticles are formed by dissolving,
encapsulating or attaching o f the drug to a matrix. Nanoparticles as a drug delivery
system have several advantageous, as given below [47]:
1)

The physical parameters of nanoparticles can be easily manipulated, depending on
type o f administration, including oral, nasal, parental, intra-ocular etc.

2)

The nanoparticles improve the stability o f drugs for control and sustained release,
which eventually regulate the drug distribution at various organs and also the
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clearance o f the drug. Indirectly, nanoparticles improve drug efficacy as well as
reduce side effects.
3)

The drug degradation can be modulated by incorporating desirable material in the
matrix composition.

4)

A site-specific targeted delivery can be achieved by conjugating targeted ligands
at the outermost surface.

5)
6

)

The chemical composition o f the drug remains intact in the nanoparticles.
The loading capacity o f the drug is relatively high.

2.3.3 Preparation Methods o f Nanoparticles
Nanoparticles have been prepared by several techniques, including solvent
evaporation, polymerization o f monomers, coacervation formation, and emulsification
methods. Among these methods, solvent evaporation and emulsification methods are
commonly used for hydrophobic drug formulations. For the solvent evaporation
technique, the polymer and hydrophobic drug are dissolved in an organic solvent. The
mixture is emulsified with an aqueous solution containing emulsifier to form an oil-inwater emulsion. Further organic solvent is evaporated by continuous stirring or by a
reduction in pressure. In addition, small size particles o f the drug are achieved by
employing homogenization or ultrasonication [48]. The emulsification method is based
upon the mixture o f water miscible solvent into a small amount o f water immiscible
solvent. Reduced interfacial tension between the two phases leads to the formation of
small particles. Particle size can be further decreased by increasing the amount o f watermiscible solvent [49].
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2.4

Ultrasonication

Sonochemistry is the research area o f reacting molecules under the influence of
ulstrasound waves. Ultrasound waves are those with a frequency range between 20 kHz
to 1 GHz. Waves with frequencies above 1 GHz are referred to as the hypersonic regime.
In physics, ultrasound waves are an important tool to understand the properties o f solids
and liquids. In addition, ultrasound waves broaden its applications including chemistry,
engineering, biology, food industry, medicine, oceanography, and seismology. Such a
wide range o f applications are based upon three unique features o f ultrasonic waves.
First, ultrasonic wave sources are inexpensive, sensitive, and reliable. Second, ultrasonic
waves travel almost

1 0 0 ,0 0 0

times slower than electromagnetic waves, which simplifies

information collection in time or create variable delay for several analyses. Third, the
ability o f ultrasound waves to pass through opaque materials provides advantages over
visible light, when images are needed from the interior o f opaque objects [50].
Ultrasonic technology is widely applicable in medical fields. Fetal images have
now become a standard part of medical diagnostics and control. The quality o f the images
is improving every year with advances in technology. There are many other areas in
medicine where noninvasive acoustic imaging of the body is invaluable, such as cardiac,
urological, and opthalmological imaging. This is one o f the fastest growing application
areas o f ultrasonics [50].
Sonochemistry brings exciting features in the field o f material science due to high
frequency waves in the liquid creating gas bubbles, which further collision o f bubbles
locally liberating high temperature (5000 K) and pressure (10 3 atm). But external cooling
systems to such high-temperature reactor lead to preparation o f material surfaces with
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specific roughness and surface chemistry for strong adhesion and also materials far from
equilibrium, e.g. nanoparticles. The implication o f varying the surface energies,
temperature and ultrasonic power on an aluminum plate surface was studied qualitatively.
Further quantitative analysis of the cavitation process may lead to the control o f the
bubble growth to a required size and thereby modify the geometry and chemistry of
surfaces and films. A detailed analysis o f nucleation of the cavitation process provides an
additional parameter to control surface treatment by ultrasound waves [51,52].

2.5

Poorly Soluble Anticancer Drugs

Still many organic and inorganic materials with significant features lack a
profound application due to low solubility in aqueous media. Over the past few decades,
several approaches including mechanical processes, chemical modifications, and
admixtures were established to improve the solubility o f the materials. Ball milling is one
among the effective processes to disperse such materials uniformly, but their powder
form is not always convenient for further applications [53,54]. Many anticancer drugs
with effective bioactivity possess extremely low water solubility due to hydrophobic
components. Thus, the formulation for such hydrophobic drugs remains a critical task in
cancer therapy. Considering new challenges similar to the aforementioned problems in
pharmaceutical industries, we need to develop the targeted delivery methods for
hydrophobic drugs into a biological environment. In most the cases, the delivery tool
should possess a biocompatible coating to reduce the enhanced permeability and
retention effect (EPR) effect [55,56].
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2.6

Paclitaxel and Its Mode o f Action on Tumor Cells

Paclitaxel is extracted from the bark and needles o f the Pacific Yew tree ( Taxus
brevifolia). On a commercial basis, paclitaxel was produced from the cell line of Taxus
Chinensis. Paclitaxel is one o f the most effective antineoplastic agents used for treatment
o f ovarian and breast cancer. It hampers tumor growth by stabilizing microtubules in the
cytoplasm and eventually ends up preventing cells in the late G2 and M phase of the cell
cycle during mitosis. Several groups reported that the binding o f taxol is specific to the
complex structure o f microtubules containing bundles and asters, which is not found in
normal cells. Paclitaxel binds to assembled microtubules with the approximate
stoichiometry o f 1 mole o f Taxol to 1 mole o f tubulin dimer, and leads to cell death by
apoptosis. In addition, the T-shaped conformation o f the Taxol side chain was proven to
fit and stabilize the microtubules. Even though several studies had been done on
paclitaxel for anticancer activity, there is a huge concern in understanding its interaction
with tubulin and other molecules as well as delivery methods for effective cancer
treatment [57,58]. Several research groups state low water solubilities o f Paclitaxel, from
0.7 to 20 pg/mL, which is a limiting factor for its clinical application [59].

2.7
2.7.1

Commercial Available Formulations o f Paclitaxel

Taxol®
Paclitaxel can be easily dissolved in ethanol, acetone, acetonitrile methylene

chloride, and methanol. Taxol® is a commonly used formulation that improves paclitaxel
solubility by dissolving it in a 50:50 (V/V) ratio o f Cremophor EL (castor oil) and
absolute ethanol. Cremophor EL is a well-known nonionic surfactant that has been used
to dissolve several other hydrophobic drugs. This formulation has a low therapeutic index
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due to non-targeted delivery towards tumor tissues and severe side effects, such as
neurotoxicity, nephrotoxicity and hypersensitivity. In order to avoid the side effects due
to organic solvents and other unsafe excipients, a few strategies for increasing solubility
o f paclitaxel include encapsulation in nanoparticles, such as liposomes and micelles and
conjugation to hydrophilic and hydrotropic compound polymer micelles [60-62].
2.7.2

Drug Complexes (Abraxane®)
Drug complexes can be formed by reacting two functional groups between the

drug and the carrier. Depending on the type o f binding units, the drug complexes are
categorized under polymer-based, oligosaccharide-based, and protein/peptide-based
vehicles. The drug complexes have no definite structure, such as liposomes, micelles or
vesicles. In order to improve biodegradability o f the drug complexes, the majority of
DDS include the drug conjugation with protein/ peptide, such as Abraxane®, which forms
a complex of paclitaxel bound to human serum albumin (Figure 2.3).
Paclitaxel nanoparticles o f a size o f about 130 nm were prepared with the help of
high-pressure homogenization. Initially, paclitaxel was dissolved in methylene chloride
and followed by the addition o f aqueous albumin under high-pressure homogenization.
The process was based upon emulsion formation of albumin at the aqueous-methylene
chloride interface. A drastic reduction o f particle size was achieved by reforming the
disulfide bonds o f albumin and crosslinking with the drug particles under the
homogenization process. Further evaporation o f methylene chloride produced drug
nanoparticles o f a size about 140-160 nm, which were carrying the amorphous structure
o f paclitaxel [63-65]. In addition to protein- drug complexes, cyclodextrin is another
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well-known drug delivery carrier. Cyclodextrin is a ring-structure oligosaccharide,
produced after enzymatic action on starch [6 6 ].

A lbum in
P aclitax el

Figure 2.3: Schematic representation o f an injectable formulation o f Abraxane , albumin
bound paclitaxel as an example o f drug-protein conjugates
2.8

Desired Properties of Low Soluble N anoparticles

For intravenous injection, a rapid clearance o f the colloidal particles occurs
through the reticuloendothelial system (RES). The rate o f particle elimination through
RES depends on several properties of the particles including surface charge,
hydrophobicity, and particle size. A previous study revealed the adsorption o f proteins on
the particle surface along with immune-responsive biomolecules. Eventually the particles
are recognized by the macrophages o f the RES and eliminated through the immune
system. Similar to in vitro studies, the amount o f polyethylene glycol decreases the
uptake o f the particles by RES [67].
Drug nanoparticle size is a key factor in cell uptake, in vivo distribution, and
release kinetics. In a Caco-2 cell line, uptake o f 1 pm particles was six fold higher than
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10 pm particles, whereas uptake o f 100 nm particles was 2.5 fold higher as compared to 1
pm particles [68,69]. For several therapeutic agents, crossing the blood-brain barrier is a
way to treat life-threatening diseases, like brain tumors. A group o f researchers developed
Tween 80 coated nanoparticles to surpass the blood-brain barrier [70]. Since
nanoparticles have large surface areas, the drug release rate is faster than for large
particles. Drug nanoparticles always face the problem o f aggregation due to their small
size during storage and transportation. The stability of the drug formulation is more
difficult to achieve as the size o f the particles is decreased further [71].
The surface properties o f nanoparticles have an important role in drug
formulations for intravenous administration. Especially the surface hydrophobicity of the
nanoparticles decide the longevity in terms o f circulation time under the immune system
(clearance by phagocytes or binding of opsonins) [72,73]. In order to improve the
circulation time, nanoparticles can be coated with hydrophilic polymers or copolymers
incorporating chains o f PEG, polyethylene oxide, and poloxamine. Specifically PEG
coated surfaces in a brush-like configuration are more anticipated as compared to the
mushroom-shape, because of less damage by the complement system as well as
phagocytosis. A variation o f PEG conformation depends on the concentration o f PEG
attached to the nanoparticle surface, as shown in (Figure 2.4)[74].
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Figure 2.4: Schematic representation o f PEG conformation on the nanoparticle surface,
mushroom-like configuration due to low surface PEG concentration and brush-like
structure due to overlapped PEG molecules

CHAPTER 3

INSTRUM ENTATION

3.1

Ultrasonicator

Ultrasound technology has experienced growth and its applications in medicine
and industry have increased over the last few decades. An ultrasonicator from Hielscher
Inc. (Germany) was used to develop a preliminary methodology to prepare nanoparticles
using sonication-assisted layer-by-layer.

3.2

Zeta-potential Analyzer

A C-Plus Microelectrophoretic instrument (Brookhaven Instruments, Co.) was
used to measure the hydrodynamic particle size and the surface charge o f nanoparticles
during each layer deposition o f the LbL assembly. The instrument was calibrated using
standard sample from the manufacturer. For each measurement, a concentrated sample of
20 pi was diluted up to 2 mL using the required solvent. The instrument can be used to
measure particle size in different solvents, such as acetone, ethanol, methanol and
phosphate buffer saline. The instrument can measure the particle size with a range
between 1 nm to 100 pm and C, potential from 200 mV to - 220 mV. In particle size
measurement mode, multi-modal sizes can be resolved to an average percentage value
based upon a set o f particle size ranges.
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Any charged particle forms different layers o f ions in closer proximity to its
surface when placed in a liquid, ^-potential analyzer measures the magnitude o f the
electrical charge at the slipping plane formation nearby the double layer. The double
layer is developed as two parallel layers o f charge surrounding a solid surface, a particle
or a liquid droplet when placed in a liquid. Two layers o f charge consist o f stem and
diffuse layers. The Stem layer, or inner region, contains strongly bound ions whereas the
diffuse layer, or outer region, represents the less firmly associated ions. The diffuse layer
forms an imaginary boundary line which is known as the slipping plane. The potential at
the slipping plane is the magnitude o f the

potential. The ^-potential value shows the

stability o f the colloidal dispersion in the liquid.
The

potential can be measured using certain theoretical models. One o f the

several models which has been used for further experiments, is dynamic light scattering.
The instrument uses an electrophoretic light scattering method to determine the particle
size and ^-potential. The instrument will help to measure ionic charge (C) per unit area of
the particle (m2).
The ^-potential measurement is based on the time-dependent fluctuation in the
scattering intensity o f the laser light passing through a colloidal solution. These
fluctuations are caused by the Brownian motion o f the colloidal particles in the solution.
Because the laser beam is monochromatic (light with a narrow frequency) and coherent
(exhibiting complete constructive interference/superposition at all times), the scattered
light undergoes constructive and destructive fluctuation by the surrounding particles.
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Confocal Microscope

In order to confirm an oppositely charged layer deposition during LbL assembly
on nanoparticles, we deposited a fluorescently labeled polyelectrolyte as the outermost
layer and observed the particles under confocal microscopy. The resolution limit of
confocal microscopy enabled the detailed structural morphology o f micron-sized particles
to be viewed. The drug nanoparticles in our experiments were observed as tiny dots
without specific structural features. The images helped to understand the deposition o f
alternative charged polyelectrolytes and suggest additional structural features to examine
under SEM.

3.4

Scanning Electron Microscope

The SEM was used to observe the shape and size o f the particles before and after
LbL assembly. The images showed the structural features o f the particles. For each
sample preparation the drug particles were centrifuged and resuspended in the required
solvent. A 2 mg/mL concentration sample was diluted using the same solvent, by
approximately ten times then placing a drop o f a few microliters on a clean silicon wafer,
and allowed to dry overnight at room temperature.

3.5

Ultra Violet Spectrophotometer

The yield o f drugs after sonication-assisted LbL assembly was measured with an
Aligent 8453 UV-Vis Spectrophotometer. A calibration curve for paclitaxel was
developed by diluting the drug in ethanol by one hundred times and measured under UVVis at a wavelength o f 227 nm. In addition, several analytical assays were based on UVVis measurements, such as pinacyanol assay. For drug release kinetics, the concentration

25
o f released drugs in PBS was dissolved in ethanol at a ratio o f 1:1 (v/v), centrifuged to
remove insoluble polyelectrolytes and measured with a UV spectrophotometer.

3.6

Quartz Crystal Microbalance

LbL deposition on a quartz crystal was measured with a quartz crystal
microbalance (QCM) (QCM200, Stanford research systems, CA). The resonant
frequency o f the crystal decreases as the mass increases. Motional resistance properties o f
the crystal depend on change in the viscoelastic nature o f the deposited layer. Prior to the
analysis o f the desired LbL assembly, the gold crystal was coated with three bilayers o f a
0.1 mg/mL concentration o f polyethylene imine (PEI) and polystyrene sulfate (PSS) in
order to develop a uniform surface on the crystal. Films o f polyelectrolytes, PLB 16-5
and Hep, with a given number o f layers (4.5 or 7.5 bilayers) were formed on the flat gold
surfaces o f 5 MHz quartz crystal resonators o f from 0.5 mg/mL aqueous polyelectrolyte
solutions in a flow chamber. Stable readings for resonance frequency (F) and equivalent
resistance (R) were obtained after each solution was kept in the cell for five minutes. In
general, the reading became stable, indicating saturation o f the polyelectrolyte, after less
than three minutes. The combination o f PEGylated and non-PEGylated polyelectrolytes
can be modified to incorporate additional PEG molecules by the addition o f a 5 mg/mL
o f mPEG5kDa-SVA or 50 mg/mL o f mPEG20kDa-SVA in distilled water for 24 hours.
Since the nanoparticles will be formulated for targeted therapy via intravenous
administration, a key feature o f the nanoparticles is the need to avoid the adsorption of
human serum proteins. In order to evaluate the preliminary data o f protein adsorption on
various amounts o f PEGylated and non-PEGylated surfaces, 1 mL o f FBS or a 40 mg/mL
BSA solution was injected further on a resonator for twenty minutes, and finally the cell
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was washed with a copious amount o f distilled water. The shifts o f resonance frequency
AF and motional resistance AR were calculated for a resonator with a film immersed in
water relative to the empty resonator in water. A mass shift after rigid film deposition
was calculated using the Sauerbrey equation [75,76].

CHAPTER 4

SONICATION ASSISTED LBL ASSEM BLY

Some sections o f this chapter are published in the following book and research
articles. The information is used by only graduate student being one o f the authors.
1)

“Making aqueous nanoparticles from low soluble materials: LbL shells on
nanocores,” Y. Lvov, P. Pattekari, and T. Shutava, Chapter
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in the book:

“Multilayer Thin Films: Sequential Assembly o f Nanocomposite Materials”,
Editors: G. Decher, J. Schlenoff, Wiley-VCH, NY, London. 2012, 151-170
(ISBN978-3 -527-31648-9).
2)

“Converting poorly soluble materials into stable aqueous nanoparticles,” Y. Lvov,
P. Pattekari, X. Zhang, and V. Torchilin, Langmuir, 2011; 27, 3: 1212-1217.

3)

“Top-down and bottom-up approaches in production of aqueous nanoparticles of
low solubility drug paclitaxel” P. Pattekari, Z. Zheng, X. Zhang, T. Levchenko,V.
Torchilin, and Y. Lvov, Physical Chemistry Chemical Physics, 2011,13, 90149019.

4.1

Introduction

In this chapter, sonication-assisted LbL (SLbL) was acquainted with many
chemical agents having low solubility (lower than <0.005 mg/mL). The aim of this work
is to overcome the constraints caused by the low solubility o f the chemicals for their
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desired applications. In comparison to several mechanical processes in Chapter 1, such as
ball milling and homogenization, we extended the scope o f top-down SLbL approach to
solubilize low solublity organic and inorganic materials. In short top-down SLbL was
studied in-detail to resolve the challenges that arose during the LbL microencapsulation
technique by G. Sukhorukov, et al. Their work was limited to nanometer-scale
polyelectrolyte shells on microtemplates with much larger diameters o f 2 to 5 pm.
Extensive additional work on LbL encapsulation did not allow the capsules to reach the
nanometer scale [8,15,77-79]. Here, the top-down SLbL approach generated stable
aqueous nanocolloids o f low solublity materials having particle diameters of 150-200 nm.
The materials included low-solublity anticancer drugs, anticorrosion agents, MRI contrast
agents, insoluble dyes, and inorganic salts. Further the work is focused on the
nanoparticulation o f a low-solublity anticancer drug, paclitaxel, as an example. Also, the
strategy o f LbL encapsulation on paclitaxel was optimized by comparing “top-down” and
“bottom-up” approaches in terms o f particle size, drug holding capacity, and release rate.

4.2
4.2.1

Material and Methods

Chemicals and Reagents
Poorly soluble anticancer drugs, such as paclitaxel, curcumin, resveratrol and

tamoxifen as well as other organic compounds, such as orange 13, gadolinium contrast
agent for MRI (gadopentetate dimeglumine - C28H54GdNs02o), 2-mercaptobenzothiazole
and 2,4-diphenylhydrazine were studied for nanoencapsulation. Inorganic compounds for
nanoparticle synthesis comprise cupric oxide, cupric carbonate, barium sulfate, iron
sulfide and manganese sulfide. Chemicals were purchased as follows: paclitaxel from
LC laboratories (Woburn, MA), curcumin from Sabinsa Corporation (Utah, USA),
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gadopentetate dimeglumine (ViewGam Inc.), resveratrol, tamoxifen, 2mercaptobenzothiazole and 2,4-diphenylhydrazine (Sigma-Aldrich, USA) were used
without further purification. LbL assembly was carried out using polyallylamine
hydrochloride (PAH), protamine sulfate and chitosan, as positively charged
polyelectrolytes, and bovine serum albumin (BSA), alginic acid, and sodium polystyrene
sulphonate (PSS), as negatively charged polyelectrolytes (used at a concentration of 2
mg/mL). All polyelectrolytes were purchased from Sigma-Aldrich. Deionized water and
PBS buffer were used at pH 7.2. For all statistical data, each experiment was repeated
three times, unless otherwise stated in the respective sections in the results. The
instruments used for the following experiments were described in Chapter 3.
4.2.2

Formation o f Nanocores: Top-down Approach
The two major approaches for experimental manufacturing techniques that allow

for a high degree o f material dispersion are top-down and bottom-up approaches [80-82].
Top-down approach involves particle disintegration via high-pressure homogenization,
ultrasonication or pearl/ball milling o f a coarse material in either water or non-aqueous
media. Powerful disruptive forces (shearing, collision, and cavitation) created by the
milling pearls disintegrate the bulk powder into nanoparticles [80,81]. Factors responsible
for the particle size of the resulting nanocrystals include the amount o f initial substance,
stabilizer, and technological parameters o f the material processing, which are variable
and highly dependent on the instrumentation used. In industry, high-pressure
homogenization and ball milling are widely used for preparing drug nanocrystals [81,82],
dye microparticles [80,83], and inorganic crystals [80]. Many FDA-approved drugs such
as Triglige®, Rapamune®, Emend®, Tricore®, Megas ES®, and Invega® have nanocrystal
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formulations. In addition several drugs are under experimental and clinical investigation
[81,82].
The top-down approach produced 100-200 nm size colloids o f inorganic and
organic low solublity drugs, dye pigments, and anticorrosion agents with stability of
about a week (Figure 4.1). The loading capacity o f the nanoparticles was up to 80 wt %
of the loaded compound; there are no free stabilizers in the solution, and they can be
concentrated up to 5 mg/mL without agglomeration.
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Figure 4.1: Chemical structures o f some poorly soluble organic compounds: a) pigment
orange-13, b) 2-mercaptobenzothiazole, c) 2,4-dinitrophenylhydrazine, d) resveratrol, e)
curcumin, f) tamoxifen, and g) paclitaxel
In a typical experimental setup for the top-down approach (Figure 4.2), the
insoluble substance (curcumin, paclitaxel), in powdered form, was dispersed in distilled
water to attain an initial concentration o f 0.5 - 2 mg/mL. For pharmaceutical application,
0.1 M phosphate-buffered saline was used to disperse the drug nanoparticles. The reactor
containing the crude dispersion was sonicated using a powerful ultrasonicator (20 kHz,
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50-100 W) and surrounded by an ice bath to maintain temperature at about 25 °C. A
polyelectrolyte, with charge opposite to that of the core material, was added to the
dispersion during the sonication at a ratio o f ~

0 .2

g per

1

g o f nanoparticles (the core).

The amount of polyelectrolyte (usually the first layer o f the polycation due to negatively
charged cores) was found experimentally to be enough to completely coat the
nanoparticles’ surfaces and reverse ^-potential to an opposite value (details are provided
in Chapter 5).
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Figure 4.2: Schematic representation o f ultrasonication-assisted top-down LbL assembly
technique
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After one hour of intense sonication, the drug particle size reaches about 200-250
nm. A second layer is deposited by the addition o f oppositely charged polyelectrolyte
(e.g., polyanion) under continouos sonication for an additional twenty minutes. Thus, the
nanoparticles o f each poorly soluble substance can be coated to obtain

200

nm diameter

particles with a polycation / polyanion bilayer. Additional layers were deposited using
conventional LbL assembly without sonication. Being predominantly negatively charged
materials, SLbL processing was carried out with positively charged poly(allylamine
hydrochloride) (PAH) or polyethyleneimine (PEI) and followed by negatively charged
poly(sodium styrene sulfonate) (PSS). For in vitro release studies o f drugs [84],
bio/polyelectrolytes (alginic acid, chitosan, heparin, poly-L-lysine (PLL)) and proteins
(protamine sulfate (PS), bovine serum albumin (BSA)) were used for the LbL process. To
prevent the formation o f larger particles and to prevent traces o f titanium from coming
out of the sonication probe during the process, all samples were centrifuged at

1 ,0 0 0

rpm

for thirty minutes.
4.2.3

Bottom-up Approach
The bottom-up technique, or nano-precipitation method, needs an appropriate

solvent to completely dissolve the nanoparticles substrate. Candidate solvents include
acetone, tetrahydrofuran, DMSO, ethanol, and N-methyl-2-pyrrolidone. Recrystallization
in nanometer-sized particles is initiated by adding highly concentrated organic solvent
into a miscible anti-solvent (often water) in the presence o f a stabilizer, and then slowly
increasing the amount of anti-solvent in the mixture. The end product can be achieved by
the elevated temperature o f the reaction media, a secondary effect o f powerful sonication,
which enhances evaporation o f an organic solvent and increases the percentage of water

33
in the media. The increased proportion o f water leads to slow oversaturation, and finally,
nanoparticle formation [84,3].
The bottom-up approach was carried out especially for anticancer drugs such as
paclitaxel and curcumin. The drug was dissolved in 60% ethanol/distilled water
(immediate crystal formation occurs in 60% acetone/distilled water). The solution was
kept under sonication for a few minutes, after which a polycation solution was added at a
rate o f 0.5 to 1.5 mL/minute. An increase in the amount of water in the solution led to a
highly polar solvent. Eventually, solubility o f paclitaxel decreased, and the nucleation
began, resulting in the formation o f nano-size particles (Figure 4.3).
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Figure 4.3: Schematic representation o f sonication assisted layer-by-layer assembly
using bottom-up approach
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Similar to the top-down approach, 0.2 g o f polycation per 1 g o f the drug was
enough to provide surface charge for colloidal stability and to restrict formation o f larger
drug particles. The drug particles can reach to a 100 nm size after about forty five
minutes o f sonication. The drug nanoparticles were washed by centrifugation at 15,000
rpm for ten minutes and re-suspended in distilled water. Immediately after resuspension,
the second layer o f polyanion was deposited to maximize the capsule surface ^-potential.
Again the nanoparticles were washed by centrifugation and paclitaxel nanoparticles with
the average particle diameter of 100 nm were obtained. Additional polyelectrolytes layers
may be further built on the drug nanoparticles using a traditional LbL process without
sonication.
4.3
4.3.1

Results and Discussion

Top-down Approach

4.3.1.1 Organic compounds
This technique was originated from the work on low solublity anticancer drug
nanoparticulation [3], but for generality, we also studied nanoparticle production from
low solubility anticorrosion agents, MRI gadolinium agent, low soluble dyes, and
insoluble inorganic salts, such as CuO, CUCO3 , and BaS(>4 . Each substance, in powder
form, was sonicated for five minutes to attain dispersion and measured surface charge
using ^-potential instrument. Almost all materials were found to have a negative surface
charge o f about 10-20 mV. The substances quickly aggregated when sonication was
stopped. After deposition o f the polycation, 200 nm diameter drug particles were
generated and their surface potential were enhanced to ±25-30 mV. Further LbL
assembly was carried out by a sequential deposition o f an anionic polyelectrolyte layer,
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changing the surface £- potential magnitude to minus 35-45 mV to attain a threshold o f
colloidal stability (Figure 4.4). Thus, an alternatively charged polyelectrolyte deposition
on the drug nanoparticles was monitored using ^-potential measurements with two
different shell compositions comprising synthetic polyelectrolytes PAH/PSS and
biodegradable polyelectrolytes chitosan/alginic acid.
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Figure 4.4: ^-potential during paclitaxel nanoparticle LbL coating via alternate
adsorption o f poly(allylamine hydrochloride) (PAH) / sodium poly(styrene sulfonate)
(PSS) and chitosan / alginic acid
The strongly charged LbL-coated nanoparticles repulse one another, preventing
aggregation and maintaining colloidal stability. Figure 4.5 shows SEM images o f
tamoxifen, paclitaxel and curcumin nanoparticles, and Table 4.1 includes their diameters,
which are about 150 - 220 nm and their shell compositions. An interesting feature o f the
top-down approach can be seen in the SEM images. Each compound produces
nanoparticles with a characteristic shape (round, rod-like, and square), which probably
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reflects the material’s crystalline structure. In the unprocessed dry powders, particles
were an average size o f tens o f microns, but after SLbL processing, there was a narrower
nanoparticle size distribution; typically ca 15% (Figure 4.5).

c

d

Figure 4.5: SEM images o f (a) original paclitaxel microcrystals and (b-d) nanoparticles
after sonication-assisted LbL assembly using top-down approach : (b) paclitaxel coated
with (PLL/heparin)4 , (c) tamoxifen coated with (PDDA/PSS) 2 , (d) paclitaxel coated with
(PAH/BSA ) 2
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Table 4.1: Experimental details for ultrasonication-assisted top-down LbL assembly o f
poorly soluble organic compounds

Organic compounds

Size before
sonication
(pm)

First layer

Second layer

Diameter
after SLbL
coating (nm)

Paclitaxel

15 ± 5

PAH, chitosan,
PLL

PSS, alginic
acid, heparin

211 ± 4 0

Tamoxifen

12 ± 7

PAH, PEI

PSS, PAA

220 ± 32

Curcumin

18 ± 5

PAH, PS

PSS, BSA

107 ± 17

19 ±

PAH, PS

PSS, BSA

264 ± 23

2 0

PAH, PEI

PSS

216 ± 2 9

8

PAH, PS

PSS, BSA

290 ± 33

pigment orange 13
2,4dinitrophenylhydrazine
2 mercaptobenzothiazole

82 ±
27 ±

6

Figure 4.6 shows an optical image of stable colloidal solutions, which have
homogeneous dispersions with permanent colors. Since confocal microscopy has a
resolution limit close to 250 nm, it cannot resolve structural features on the shell wall of
200 nm diameter nanoparticles. For paclitaxel, we coated an outermost layer with FITC
labeled chitosan (polycation) and captured fluorescent images o f colloids using a
confocal microscope (Figure 4.6).
Thus, the adsorption of the polyelectrolyte layer on the particles was visualized
with the same technique that resolved the LbL coating labeled with fluorescent FITC,
except that the sonication time was shortened to about ten minutes. Figure 4.6 (b) is a
fluorescent confocal image o f a micron-size capsule cross-section, where the green shell
is the polyelectrolyte capsule wall.
Many effective anticancer drugs, such as paclitaxel, curcumin and tamoxifen, lack
efficient formulation for intravenous administration because they are poorly soluble in
biological solvents. The natural form of the drugs (micron size) cannot pass through the
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tumor, which usually has a nanopore cutoff size. An important task for researchers is to
develop stable nanoparticles for cancer treatment. The similar approach o f SLbLencapsulation can be useful for MRI gadolinium contrast agent (gadopentetate
dimeglumine), which must be converted from 5-8 micron sized particles into stable
submicron colloids o f 400 ±

1 0 0

nm diameter particles.

Figure 4.6: (a) Photograph o f stable nanoparticles o f orange 13, cupric oxide, 2,4dinitrophenylhydrazine and paclitaxel, and (b) confocal fluorescent images o f five micron
paclitaxel particle after ten minutes SLbL treatment assembly using top-down approach
(FITC labeled chitosan was used in the shell wall)
The SLbL-approach was applied to poorly soluble dyes and anticorrosion agents
for their nanoparticle development (orange 1 3 ,6-mercaptobenzodiazole and 2,4diphenylhydrazine). During SLbL processing, the particles were coated with positively
charged poly(allylamine hydrochloride) (PAH) and followed by negatively charged
poly(sodium styrene sulfonate) (PSS) as a second layer. Ultrasonication-assisted LbL
assembly reduced the initially micron sized particles to 200-290 nm size particles (Figure
4.7). These colored nanoparticles were stable for months.
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b

Figure 4.7: SEM images o f orange 13, (a) before and (b) after SLbL coating
Inorsanic compounds

4.3.1.2

The top-down approach also produced inorganic compound nanoparticles. Results
from Figure 4.8 and Table 4.2 showed a reduction in particle diameter from 10-50
microns in the initial powder, to an average o f 250 nm, with ^-potential o f ca - 40 mV.

Table 4.2: Experimental details for ultrasonication-assisted layer-by-layer assembly of
poorly soluble inorganic compounds
Inorganic
compounds

Initial
particle size
(pm)

First layer

Second layer

Particle size
after SLbL
coating (nm)

CuO

15 ± 2 3

PAH, PS

PSS, BSA

175 ± 2 0

CuCOs

50 ± 17

PAH, PEI

PSS

199 ± 2 5

PAH

PSS

120 ± 5 0

PAH

PSS

160 ± 3 0

BaS0 4

6

±3

FeS

40 ±

MnS

50 ± 2 0

PAH

PSS

230 ± 20

Al(OH ) 3

30 ± 15

PAH

PSS

225 ± 25

8

40

a

b

c

Figure 4.8: SEM images o f poorly soluble inorganic materials: cupric oxide before (a)
and after (b) SLbL coating with PAH/PSS bilayers, and (c) nanoparticles o f barium
sulfate coated with (PAH/PSS )2
The top-down approach, using SLbL, was carried out to solubilize several of the
insoluble inorganic salts listed in Table 4.2. We have sorted inorganic salts into three
general groups: oxides, hydroxide, and sulfides. Among all o f the salts, sulfides are the
most insoluble o f the inorganic compounds. The top-down approach using SLbL failed to
convert nanoparticles from the crushed powder o f a silicon wafer, possibly because the
bonds in the covalent crystal were too strong. The converted nanoparticles will be useful
for industrial application in composite materials.
4.3.1.3

Anticancer drug: Paclitaxel
The top-down approach was studied in general for several poorly soluble

materials. In this section, the approach was optimized using paclitaxel as an example of
an anticancer drug, and to understand the implication o f the process in-depth.
Experiments were carried out to achieve a desired nanoparticle size of nanoparticles
diameter and to determine appropriate polyelectrolytes concentrations.
Figure 4.9 shows the nanoparticle diameter as a function o f sonication time. The
diameter reached 200 nm after two hours o f sonication. Since the nanoparticles are not
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stable with the first polycation layer, each particle size measurement in the graph was
taken after subsequent deposition o f the polyanion layer. For each time point in the graph,
the nanoparticles were first coated with the polycation layer and then coated for fifteen
minutes with the polyanion layer (For example, samples with 45 minutes o f sonication
time were sonicated for thirty minutes for the cationic layer and then sonicated for fifteen
minutes for the anionic layer). The yield of nanoformulated paclitaxel in the top-down
approach was about 90%, which was confirmed using UV-Vis measurements (Appendix
A).

600
400

200

Sonication time (minutes)
Figure 4.9: The particle size o f paclitaxel in response to ultrasonication time (top-down
approach)
The slow increase in particle size o f paclitaxel with up to one hour of sonication
time during the top-down approach may be caused by the formation o f polyelectrolyte
complexes and uneven polyelectrolyte adsorption on large drug particles. After one hour,
a continuous decrease in particle size confirmed the uniform layering o f polyelectrolytes.
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In addition, the C, potential value was found to be close to - 25 +/- 3 mV which was a sign
o f a stable colloidal dispersion.
After optmising the sonication time, we began to improve the approach for
minimal utilization of polyelectrolytes. Experiments were carried out to determine the
effect on paclitaxel nanoparticles by varying the amount o f chitosan and alginic acid as
polycation and polyanion layers, respectively (Table 4.3). An advantage o f the process
was to eliminate a tedious washing step after each deposition layer as compared to the
conventional LbL technique. So the stability o f the nanoparticles was retained only after
one bilayer using a washless LbL process. The surface ^-potential and nanoparticle
diameters were measured immediately after the deposition o f two layers. The
nanoparticles were centrifuged at 15,000 rpm for ten minutes to separate out unreacted
polyelectrolytes in the supernatant. The nanoparticles were resuspended in distilled water
and stored at 2 °C for future experiments.

Table 4.3: A list o f experiments for the optimization of polyelectrolytes amount
for paclitaxel nanoparticles
Concentration Amount o f Sonication Amount of Sonication Particle
Z
o f paclitaxel chitosan as 1 st time
alginic acid as
time
size
potential
(mg/mL)
layer
2 nd layer
(min)
(nm)
(mV)
(h)
(mg/mL)
(mg/mL)
0.5

0 .1

1

0 .1

20

887 ± 7

-30 ± 5

0.5

0 .1

1

0 .2

20

240

-35 ±

0.5

0.15

1

0 .2

20

190 ±

0.5

0 .2

1

0.3

20

260 ± 9

± 6

8

8

-33 ± 3
-30 ± 7
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4.3.2

Bottom-up Approach
The bottom-up approach leads to more disintegration and smaller particle

diameters than the top-down approach. The process is based upon several parameters in
order to attain the nanoparticles of the desired size. In the beginning, the drug was
dissolved completely at an initial concentration o f 0.5-2 mg/mL in a mixture o f
predominately organic solvent to distilled water. Further precipitation of the drug was
promoted by evaporating the solvent under continuous sonication and also increasing the
amount of distilled water. The solubility o f paclitaxel decreased with increased water
concentration. The saturation o f the drug crystals then increased in the presence o f
polyelectrolyte and shifted to form similarly-charged nanoparticles that repelled each
other.
The top-down SLbL method provided a higher yield than the bottom-up approach.
The average particle diameter o f paclitaxel during the bottom-up approach reached 100
nm, whereas the smallest particle diameter for the top-down approach was about 2 0 0 nm.
Experiments were carried out to optimize the drug particle size depending on
alcohol/water ratio for the initial drug solution, primary drug concentration, sonication
power and time, and rate of water addition for nucleation initiation. Particle size was
affected by a change in the rate o f water addition and by the initial drug concentration in
60% ethanol (Figure 4.10). The ratio o f polyelectrolyte mass to paclitaxel mass was kept
constant throughout all experiments. The increase in water addition rate leads to faster
crystal nucleation and ultimately increases the particle size (Figure 4.10 (a)). The particle
size was increased gradually from 120 nm to 225 nm, since the rate o f water addition was
increased from 0.5 to 2 mL/minute. So the rate o f water addition needs to be less than or
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equal to 0.5 mL/minute. An increase in the initial drug concentration promoted
aggregation during the nucleation and increased the particle diameter (Figure 4.10).
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Figure 4.10: Particle size o f paclitaxel during bottom-up SLbL process depending on (a)
rate o f water addition, and (b) initial paclitaxel concentration
4.3.3

Zeta-potential Analysis
Alternately charged polyelectrolyte deposition on paclitaxel nanoaprticles was

confirmed by ^-potential measurements. The uncoated paclitaxel was found to have a
negative surface charge, and a polycation was deposited as the first layer on the particles.
LbL assembly was applied with synthetic and natural-sourced polyelectrolytes. Initial
LbL assembly on the nanoparticles was confirmed using two bilayers of the highly
charged molecules PAH/PSS. LbL assembly o f natural-sourced polyelectrolytes can be
advantageous for the development o f paclitaxel formulation for intravenous
administration. Successful attempts o f bottom-up LbL assembly were made using two
bilayers o f chitosan/alginic acid and protamine sulfate/bovine serum albumin (Figure
4.11). ^-potential values were similar between both combinations, so the nanoparticles
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did not show any significant change in terms o f stability. Based on the application, LbL
assembly can be modified depending on the molecular weight and surface charges o f the
polyelectrolytes.
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Figure 4.11: ^-potential o f paclitaxel coated with two different bilayers o f
chitosan/alginic acid or protamine sulfate/bovine serum albumin using bottom-up
approach
4.3.4

Paclitaxel Release Kinetics
LbL modification o f the surface o f organic crystals and microparticles to extend

release time has been explored by many researchers [4-16, 19]. Beginning with the paper
by Antipov, at el. [85] on fluorescein crystals coated with PAH/PSS shells of 5-15
bilayers, a number o f reports demonstrated that release time could be controlled within 1 ten hours with increasing wall thickness o f polyelectrolyte microcapsules [86,87].
Biocompatible microshells based on 10-12 chitosan/dextran sulfate and chitosan/alginic
acid bilayers have been reported to decrease the release rate for ibuprofen microparticles
from seconds to a few hours [79,88].
For poorly soluble materials, anticancer drugs restrict their formulation due to low
dissolution rate. So the release kinetics o f poorly soluble drugs can be studied only when
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the concentration o f the drug is lower than its solubility limit. The release kinetics o f
paclitaxel nanoparticles were studied with a different number o f PAH/BSA layers under
sink conditions (Figure 4.12). The release curves were fitted with Peppas’ exponential
model [89].
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Figure 4.12: Release from paclitaxel nanoparticleal particles with SLbL top-down
approach: protamine sulfate coating (PS) -1 , original paclitaxel without coating - 2, and
(PS/BSA ) 3 coating - 3 (in water at 37 °C)
Here, the release study o f uncoated paclitaxel was compared with 0.5 and 3
polyelectrolyte bilayer coatings. Though the samples were coated with a different number
of layers, due to an initial burst, at least 2 0 % o f the total paclitaxel were solubilized
within fifteen minutes, followed by a slow release under sink conditions. Similar release
rate results were obtained for the bottom-up approach in paclitaxel nanoparticulation.
Paclitaxel that was coated through the top-down approach with one layer o f protamine
sulfate had a rapid release rate because the particle size was about 180 ± 20 nm. The
release rate decreased with the number o f layers.
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In the proposed paclitaxel formulation, nano-scale drug particles were obtained,
and the nanocapsules contained a high drug content o f 80-90% due to very thin capsule
walls (of ca 10 nm, as was estimated from Quartz Crystal Microbalance measurements of
the LbL multilayers of corresponding compositions).

4.4

Discussion

Although the methodology o f nanoparticle preparation seems reliable in terms of
utilization o f the materials and time, many key features were noted down for the
development of sonication-assisted LbL assembly in future studies. First, the effect o f the
polyelectrolyte adsorption on the nanoparticle surface was not only limited to surface
charge. It may also refill or overcome physical damage to the particles. LbL assembly,
depending on the molecular weights o f the polyelectrolytes, might be an essential factor
to analyze physico-chemical properties o f the particles and to optimize the SLbL for
desired application. Second, the ^-potential o f all uncoated materials was negative, which
could be caused by oxidation o f the material under powerful sonication. The assumption
can be tested by maintaining experimental conditions in presence o f an inert gas
atmosphere.
Third, several attempts to optimize SLbL would not produce particle diameters
smaller than 200 nm. This size limit might be associated with the nucleation o f vapor
bubbles. Such a particle size barrier can be overcome by using bubbling agents, such as
ammonium bicarbonate, which will decompose without damaging the original drug
product. Also the efficiency o f sonication can be improved under high pressure
conditions while at the same time avoiding losses due to high temperatures [52]. Our
preliminary results showed promising results as a further decrease o f particle size. Fourth,
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nanoparticles had drug-dependent characteristic shapes under SEM, such as rectangular
for curcumin and paclitaxel, and spherical for tamoxifen.

4.5

Conclusion

In the past two decades, several articles were published on microcapsules coated
with LbL assembly. The majority o f work focused on the optimization o f shell
composition and its structure, shell permeability, release rate depending on the number of
layers, and effects o f the LbL shell on various biological applications. The novelty of our
work is a drastic decrease in particle size from micron to

2 0 0

nm scale due to the

combined effects o f sonication and LbL assembly [85].
We carried out LbL assembly on paclitaxel particles with natural and synthetic
polyelectrolytes, including PAH, PSS, chitosan, alginic acid, protamine sulfate, and BSA.
The nanoparticles were precipitated much faster for the case of protamine sulfate (as
polycation) and BSA (as polyanion) due to insufficient surface potential. Otherwise, the
composition o f LbL assembly o f chitosan/alginic acid and PAH/PSS can be used to form
stable nanocolloids of about 150 to 200 nm and up to 1 mg/mL concentration. Thus, the
solubility o f paclitaxel nanoparticles reached
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times higher than its usual solubility in

water. Titanium oxide microparticles were eroded from the sonotrode (sonicator probe) in
both top-down and bottom-up approaches, and can be separated out using centrifugation
at 1,000 rpm for twenty minutes. A loss o f particles during titanium dioxide separation
was calculated at about ca. 10% o f the total paclitaxel concentration. In addition, the fast
nucleation rate in the bottom-up approach generated large particles that were also
separated out by centrifugation. Thus, the yield rate is lower for the bottom-up approach
than for the top-down approach.

CHAPTER 5

BOTTOM-UP APPROACH BASED ON W ASH LESS ASSEM BLY

Some sections of this chapter are published in the following research article. The
information is used by only graduate student being one of the authors.
“Architectural layer-by-layer assembly o f drug nanocapsules with PEGylated
polyelectrolytes” Shutava T., Arapov K., Pattekari P., Torchilin V., and Lvov Y., Soft
matters, 2012, 8 , 9418-9427.

5.1

Introduction

In the previous chapter, we have optimized the particle size of paclitaxel
nanoparticles that were generated through sonication assisted LbL assembly. The
advantages and disadvantageous o f the top-down and bottom-up approaches were
analysed to choose the best option for the nanoparticle preparation. The following
shortcomings from two established methods need further improvement.
1)

High-energy release of titanium dioxide from the sonotrode during the sonication
causes contamination. The need to separate out the unwanted particles decreased
the yield o f the end product.

2)

The total concentration o f paclitaxel in the end product was about 0.5 mg/mL,
whereas the intravenous injection formulation requires a concentration o f at least
1 mg/mL (e.g. in vivo studies on mice). Several processing steps, involving
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centrifugation, are needed to achieve the desired concentration. Such post
treatment o f the end product could lead to a loss in the number and stability o f the
nanoparticles in the dispersion.
3)

The desired particle size o f paclitaxel was achieved after about 1 hour of
sonication. The total sonication time needs to be decreased to improve the
efficiency of the process.

4)

The synthesis o f paclitaxel nanoparticles was begun using industrial-scale
ultrasonicator (Heilscher 1OOOhd). The maintenance o f several physical
parameters during sonication, such as temperature and high strength containers,
require extra precautionary actions. Considering the aforementioned issues due to
the existing methods using industrial-scale ultrasonicator, an efficient way of
nanoparticles synthesis can be developed using a bath sonicator.
Our architectural approach to build-up nanocapsules includes preparation o f

hydrophobic PTX nanocores in the presence o f amphiphilic or polymeric surfactants
followed by deposition o f thin multilayer shells o f PEGylated polycations/polyanions
using the washless LbL assembly technique (Figure 5.1). Amphiphilic surfactants
prevent initial drug nanocrystals from coalescing upon core preparation and serve as
anchors for attaching polycation/polyanion shell that plays a dual role in the nanoparticle
stabilization. The inner layers further improve nanocore inaccessibility for
recrystallization into larger particles, whilst the outermost layers enhance colloid stability
due to high hydrophilicity of the polyelectrolytes. Incorporation o f polyethylene glycol
(PEG) moieties in the LbL shell by using PEG-modified polyelectrolytes further
increases the colloidal stability of the dispersions and attains some protein-resistant
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properties. The LbL shell architecture can be developed further for anchoring tumor
targeting agents through amine groups available at the outermost polyelectrolyte layer.

nanocore preparation

washless Layer-by-Layer polyelectrolyte assembly

y separation
* rinsing

in PBS butler containing uncharged stabilizers

Figure 5.1: Scheme o f drug nanocore preparation and washless LbL coating. The image
on right side shows visualization o f a dollar coin through stable nanocolloids dispersion
o f paclitaxel
5.2
5.2.1

Experimental Details

Materials
Paclitaxel (PTX) was obtained from LC Laboratories, USA. Poly-L-lysine (PLL),

heparin sodium salt (Hep), bovine serum albumin (BSA), BSA-fluorescein labelled
(BSA-FITC), PLL-fluorescein labelled (PLL-FITC), polystyrene sulfonate (PSS),
polyethyleneimine (PEI), polyvinylpyrrolidone (PVP), Polysorbate 80, sodium docusate
(AOT), phosphate buffered saline (PBS), pinacyanol chloride, ethanol, acetonitrile,
dimethyl sulfoxide (DMSO) and acetone were obtained from Sigma-Aldrich and used as
received. Fetal bovine serum (FBS) was obtained from Atlanta Biologicals, USA.
Block-copolymers o f poly-L-lysine or poly-L-glutamic acid with polyethylene
glycol (PEG) o f different molecular weights were obtained from Alamanda Polymers,
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USA. mPEG5kDa-SVA and mPEG20kDa-SVA were obtained from Laysan Bio
Incorporation, USA.
The copolymers have different PEG/PLL unit ratios varying from 1.1 to 4.5 for
the first two block co-polymers with smaller PLL molecular weight and 2.8 for higher
molecular weight block copolymers: 1) PLL[16kDa]-b-PEG[5kDa] (PLB16-5), 2) PLL
[16kDa]-b-PEG[20kDa] (PLB16-20), 3) PLL[33kDa]-b-PEG[20kDa] (PLB33-20), 4)
PGA[3OkDa]-b-PEG[20kDa] (PGB30-20). Grafted copolymer o f PLL 65kDa and PEG
5kDa with a grafting ratio o f ca. 4.5 (PLG65[4.5]5) was synthesized [90]. Copolymer of
PLL 20 kDa and PEG 2 kDa with a grafting ratio o f 3.3 (PLG 20[3.3]2) was obtained
from SuSoS, Switzerland. For all statistical data, each experiment was repeated three
times, unless otherwise mentioned at the respective sections in the results.
5.2.2

Drug Nanocapsules Preparation

5.2.2.1 Paclitaxel nanocores
PTX crystals were dissolved in acetone at 80 mg/mL and 63 pL o f the
concentrated solution was added to 2.8 mL o f PBS buffer containing 2.9 mg/mL PVP, 1.2
mg/mL AOT, and 0.36 mg/mL Polysorbate 80 at 10 °C under continuous sonication in a
Branson ultrasound bath. The mixture was sonicated for 20 minutes to allow less than
180 nm PXT cores to be formed.
5.2.2.2 Formation o f volvelectrolvte shell by non-washing LbL method
The drug nanocores were coated in a supernatant containing the excipients
mentioned above with polyelectrolytes using a non-washing LbL procedure [91].
Typically, each polyelectrolyte in small 15-25 pL aliquots o f a concentrated 60 mg/mL
solution was added to 2.5 mL dispersion o f nanocores under constant sonication. The
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amount of a polyelectrolyte needed to recharge surface o f the nanoparticles was evaluated
as described below. After addition o f each polyelectrolyte, the nanoparticles were kept
for five minutes and then the next polyelectrolyte was added. No intermediate washing of
nanoparticles was done until the shell was complete. Typically, 3-7 polycation /
polyanion double coatings were deposited.
The LbL assembly was followed by (^-potential (in distilled water) and
hydrodynamic diameter (in PBS) measurements (ZetaPlus Brookhaven). After the LbL
shell was complete, the coated nanoparticles of ca. 200 nm diameter for PXT was
separated from the supernatant by centrifugation, re-dispersed in PBS buffer, and kept as
stable colloids o f 2-5 mg/mL concentration. The yield o f the LbL-coated nanoparticles
varies with the applied coating and was ca. 50-90 % o f the initial drug amount.
Scanning and transmission electron microscopy (SEM, TEM) and laser confocal
scanning microscopy (CLSM) images o f LbL-coated nanoparticles were taking with a
Hitachi S-4800, a Zeiss EM912, and a Leica D M IR E2 instruments. UV absorbance was
measured with an Agilent- 8453 UV-vis spectrophotometer.
5.2.3

Characterization o f Non-washing LbL Assembly o f Polvelectrolvtes

5.2.3.1 Evaluation o f polvelectrolvte amounts to reverse surface charge
Dispersions o f PTX nanoparticles coated with a (PLL/Hep)n or (PLB16-5/Hep)„ ,
n=0-1.5 shell in the supernatant were prepared as described above. A

6

mg/mL

polyelectrolyte, oppositely charged to the nanoparticles, in 20 pL aliquots was added to
the dispersion under short sonication until the surfaces o f the nanoparticles were
completely recharged. After each sonication, 0.12 mL was withdrawn from the dispersion
for (^-potential and pinacyanol assay evaluation o f the amount o f negative charges in the
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dispersion. The partially-coated nanoparticles were separated from the probe by
centrifugation and were redispersed in DI water. The number o f negative sites in a
sample was evaluated per 1 mg o f the drug using the pinacyanol assay [92-94].
5.2.3.2 PVP influence
To evaluate the PVP influence on the amount of polyelectrolytes to be added to
recharge surface of nanoparticles, 1.5 mL of uncoated PTX nanoparticles in the
supernatant containing the surfactants was diluted either with 1.5 mL o f PBS buffer (pH
7.4) or with 1.5 mL o f 2.8-11.2 mg/mL PVP solution in the buffer. The aliquots
containing 30 pg o f PLB16-5 were step-wise added to the mixture until the ^-potential of
the LbL-coated nanoparticles reached a high positive (+30 mV) value. After this C,potential was reached, Hep was added in the same way. The formation o f two PLB 165/Hep bilayers followed.
5.2.4

Analytical Techniques

5.2.4.1 Pinacyanol assay for negatively charged sites
Typically, 20-80 pL o f a diluted sample in distilled water was added to 2 mL o f a
pinacyanol solution with Ao = 0.50+0.05 at 600 nm [92-94]. The UV-Vis spectra were
recorded two minutes after mixing. The concentration o f negative sites (in pmol/mg
PTX) was calculated for the nanoparticles and for the polyelectrolyte dispersion in
supernatant. The experimental data o f negatively charged sites were compared with the
mathematical results based upon certain assumptions (Appendix B ) .
5.2.4.2 Drug concentration
PTX concentration in the LbL-coated colloids was estimated after extraction o f
the drug with ethanol, using UV-vis spectroscopy (227 nm). All colloids were redispersed
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in PBS before the extractions. The content o f drugs on a dry weight basis was evaluated
in lyophilized LbL-coated dispersions.
5.2.5

Characterization o f Colloidal Stability o f Drug Nanocapsules
Colloidal stability o f concentrated 3 mg/mL dispersions o f LbL-coated paclitaxel

nanoparticles in PBS buffer was evaluated at 24 hours intervals up to two weeks. The
samples were kept at room temperature. Aliquots of 10-25 pL were dispersed in 2 mL
PBS, and the apparent hydrodynamic diameter o f the nanoparticles was measured. To
evaluate the stability o f LbL-coated nanoparticles in serum, 100 pL of a sample under
investigation was added to 2 mL o f FBS, and the position o f the nanoparticles peak in the
mixture size distribution was measured at 24 hours intervals up to two weeks.
5.2.6

Enhancing o f PEG Modification o f LbL-coated PTX Nanoparticles
The powder o f mPEG5kDa-SVA or mPEG20kDa-SVA was directly added to the

dispersion o f nanoparticles with a positively charged outermost layer (PLB16-5) in PBS
buffer at pH 7.2 to achieve the PEGylator concentration o f 5-50 mg/mL and the mixture
was vigorously shaken and sonicated for thirty seconds to dissolve the PEGylator. The
dispersion was kept for ten hours at 4°C. The nanoparticles were separated by
centrifugation at 14,000 rpm for ten minutes and resuspended in PBS at pH 7.2.
A PEGylating agent was dissolved in the dispersion of PTX nanocapsules with a
(PLB16-5/Hep)5.5 or (PLB16-5/Hep)7 5 shell. All samples initially have ~1.5 mg/mL PTX
nanoparticles. After 24 hours, the nanoparticles were separated by centrifugation and
redispersed in PBS buffer. The number o f-N H 2 groups in the samples were estimated
using the methylene blue-heparin assay [94] using free PLB16-5 for calibration. PTX in
collected samples was assayed by UV-vis at 227 nm (Appendix A).
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5.2.7

Characterization o f Drug Release from Nanoparticles
The in vitro release studies for the paclitaxel nanoparticles were done at sink

conditions at 37 C in PBS buffer containing 0.2 mg/mL Polysorbate 80, which was
added to increase drug solubility limit. The LbL coated drug nanoparticles were added to
the release medium at a concentration three times lower than the drug solubility limit;
aliquots were withdrawn after certain time intervals and the drug concentration in
supernatant was measured after removing nanoparticles by centrifugation at 14,000 rpm
for ten minutes.
5.2.8

Quartz Crystal Microbalance Analysis
To understand protein-resistant properties o f PEGylated polyelectrolyte films,

layer-by-layer assembly o f several combinations o f Hep and PLL or PLB on flat surfaces
has been studied by quartz crystal microbalance technique, with motional resistance
monitoring (QCM-R), in a liquid flow cell (QCM200, Stanford Research Systems) [75,
76]. Aqueous 0.1 or 0.5 mg/mL solutions of the polymers were used. The solutions (1
mL) and DI water (2 mL) were injected into the liquid flow cell with an inserted 5 MHz
resonator, having an additional (PEI/PS S) 3 precursor layer on its gold working surface, in
the following order (H 2 0 /polycation/H 2 0 /heparin)n. Each solution was kept in the cell for
five minutes until stable readings for resonance frequency (f) and equivalent resistance
(R) were obtained. Usually three minutes were required to reach the saturation of
polyelectrolyte adsorption on a polyelectrolyte-modified surface. All changes o f f and R
were referenced to the values obtained when the resonator, without a film, was immersed
in distilled water. The film mass was calculated from the Sauerbrey equation for rigid
deposits [75,76].
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To evaluate protein adsorption on LbL coating o f different architecture, 1 mL of
FBS or a 40 mg/mL BSA solution in water was injected in the liquid flow cell with a
resonator coated with different combinations o f PEGylated and non-PEGylated
polyelectrolytes for five minutes. Then the cell was washed with 2 mL of DI water and
resonator parameters were monitored for additional ten minutes.
mPEG5kDa-SVA or mPEG20kDa-SVA in water was used in order to enhance
PEG concentration on the existing layers for further resistance to serum protein binding.
After 7.5 bilayers o f PLB 16-5/Hep were assembled on a resonator, a 5 or 50 mg/mL
solution o f mPEG5kDa-SVA or mPEG20kDa-SVA in water was injected into the cell for
24 hours. The unreacted PEGylator was removed from the cell by rinsing it with water.
The attachment o f proteins from fetal bovine serum was monitored for twenty minutes,
and finally the cell was washed four times with 5 mL o f distilled water.

5.3
5.3.1

Results and Discussion

Drug Nanocores
After switching the method o f nanoparticle preparation from industrial sonicator

to laboratory-scale bath sonicator, the bottom-up method efficiently generated to prepare
200 nm diameter paclitaxel particles. This approach can be divided into two major steps,
nanocore preparation in the presence of surfactants, followed by LbL assembly on the
surfactant-coated nanocores. In the beginning, nanocores were formed by precipitation of
drug nanocrystals from water-miscible solvent in presence o f surfactants (mentioned in
materials, AOT, Tween 80 and PVP). After adsorption o f the surfactants on the
nanocores, the overall anionic charge was developed on the particle surface. The
nanocores were found semi-stable, which lowered the rate o f recrystallization. Since
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paclitaxel is well known to recrystallize very fast [96-98]; thus, the uncoated dispersion is
stable for less than thirty minutes. In order to improve the stability o f the nanoparticles,
LbL assembly needs to be carried out immediately after the formation o f the nanocores
(Figure 5.2).
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Figure 5.2: Colloidal stability o f LbL- coated paclitaxel nanoparticles (prepared in water)
in different media. Shell: a) (PLL/Hep)4/PLL b) (PLG65[4.5]5/Hep)4
Aiming for stable nanocolloids o f the particles in PBS, we deposited several
bilayers o f PEGylated as well as non-PEGylated polyelectrolytes on the surfactant coated
nanocores. The stability o f nanoparticles coated with PEGylated and non-PEGylated
polyelectrolytes were observed by measuring the hydrodynamic diameter of the particles.
A typical paclitaxel nanoparticle size was about 170-180 nm.
Paclitaxel nanoparticles coated with PEG-modified polyelectrolyte shells were
slightly larger than the non-PEG coated samples. Nanoparticles were found with
elongated shapes o f 250 nm in length and widths o f 50-70 nm (F igure 5.3).
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Figure 5.3: a-d) TEM images o f PTX nanoparticles coated with a (PLB165/Hep)3/PLG65[4.5]5 shell (a, c, d, stained with ( N H ^ V ^ O y ) and with a (PLB165 /Hep ) 5 5 shell (b, stained with UC>2 (CH 3 COO) 2 )
In TEM images of a nanoparticle, one can distinguish crystal faces and borders.
Under confocal microscopy, the outermost layer o f FITC-labeled BSA was visualized to
confirm the LbL assembly, but the ability to assess the shapes o f individual nanoparticles
was limited by the resolution o f the microscope.
5.3.2

Anchoring Laver: Surfactants
Among all the excipients and surfactants, AOT was the only charged molecule

(anionic), and it needs to be considered in order to carry out further LbL assembly. In
addition, AOT is FDA-approaved for medical usage and considered to be safe in food
products. Before we chose AOT as a key molecule for paclitaxel preparation, we tested
several water-soluble negatively charged amphiphilic (non-lipid and non-protein)

60
surfactants in terms o f the recovery o f paclitaxel nanoparticles o f the desired size as well
as the amount o f surfactant adsorbing on the drug surface (T able 5.1).

Table 5.1: Content o f surfactants adsorbed on PTX colloids
Surfactant

Recovery of
crystalline PTX
nanoparticles, %

Docusate sodium salt
(AOT)
Glyclic acid ethoxylate
oleyl ether (Oleth - 6
carboxylic acid)
Glycolic acid ethoxylate
lauryl ether (Laureth - 6
carboxylic acid)
Dodecyl sulphate sodium
salt (SDS)
SDS- no PVP
Poly(maleic acid-coolefin) sodium salt

Hydrodymanic
diameter, nm

84.2±7.4

Amount o f
surfactant,
remaining
adsorbed on
nanoparticles,
pmol/mg PTX
1.03±0.23

89

0.56

92.5±2.5

64

0.65

126.6±2.5

76

0.17

2000-9000

-1 0 0

0.27
0.17-0.25

-300
122.5±2.0

“

140-210

The amount o f each surfactant adsorbed on the paclitaxel nanocore was calculated
using the Pinacyanol assay for negatively charged sites. AOT adhered more strongly to
the drug nanocrystals and providing a higher negative surface charge density than the
other surfactants. As per the calculations, paclitaxel nanocores can be coated with
1.03±0.23 pmol AOT per 1 mg o f the drug.
From the amount o f AOT adsorbed on the paclitaxel surface, we estimated the
amount o f polysorbate 80 and PVP for synergetic effects to stabilize the nanoparticles.
Since PVP plays an important role as a stabilizing agent, it can be removed further from
the concentrated solution o f coated paclitaxel by washing with PBS. The nanoparticles in
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the presence o f AOT and PVP were stable in distilled water, whereas they crystallized
soon after resuspension in PBS. Thus Tween 80 improves the colloidal stability o f the
nanoparticles in PBS. An approximate ratio o f amphiphilic surfactants (AOT and Tween
80) to paclitaxel was calculated about 0.5-0.7 g/g. In addition to AOT and Tween 80, 2.9
mg/mL concnetration o f PVP was necessary to obtain paclitaxel nanoparticles less than
200 nm. The optimized amount of the surfactants did not affect the LbL assembly. At
some point, an excess amount o f AOT remains unbound to the surface and forms
complexes with PLB at a charge binding ratio o f 1: 1. These complexes became coated
through the same electrostatic mechanism that coated the paclitaxel particles, but they
lacked the paclitaxel core. Other hydrophobically modified polyelectrolytes, such as
imidazolyl, cholesteryl, deoxycholic acid conjugates o f chitosan can be good candidates
for the anchoring layer in such shell architecture [99-101].
5.3.3

Amount o f Polyelectrolvtes to Reverse Surface Charge During LbL Shell
Formation
The conventional method o f washing after each LbL layer deposition is not

suitable for poorly soluble drugs. The multiple washings may boost recrystallization and
generate hard to generate particle sizes much larger than the desired 200 nm. Therefore, a
non-washing assembly technique was developed to overcome recrystallization.
During non-washing assembly, the exact amount o f each polyelectrolyte during
the first two bilayers was measured using a titration method to reverse the surface charge
and then use the same amount for further coatings. LbL assembly o f cationic PEGmodified PLL (PLB 16-5) and Hep on paclitaxel cores had the best colloidal stability.
Similar particle sizes were found with the unmodified PLL in alteration with Hep, but the
colloidal stability was much lower. Alternating layers o f unmodified polylysine with
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anionic heparin gives similar results, but with much lower colloidal stability. As
positively charged PLB 16-5 is added to the drug nanocores, their ^-potentials increase
(Figure 5.4 a). The total number o f negatively charged sites in the dispersion was
determined with the pinacyanol assay (lower panels of Figure 5.4). The dye in the
pinacyanol assay attached to the negatively charged AOT (anionic surfactant) sites on the
cores. The negatively charged sites decreased after addition o f PLB 16-5. Eventually,
increase o f positive charges and decrease o f available negative sites for the dye recharges
the particle. From the assay and ^-potential readings, 0.26 mg o f PLB 16-5 per 1 mg o f
paclitaxel was necessary for charge reversal (Table 5.2). For the second assembly step,
coating with anionic heparin, a moderate increase in negative sites on nanoparticles was
nevertheless sufficient to decrease their (^-potential to the initial value, before the first
assembly step (Appendix B).
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Figure 5.4: Changes o f (^-potential (upper row) and number of negative sites estimated
by pinacyanol assay (lower ro w ) in the process o f step-wise addition of a) PLB 16-5 to
PTX/AOT cores, b) Hep to PTX/AOT/PLB16-5 nanoparticles, c) PLB 16-5 to
PTX/AOT/PLB 16-5/Hep nanoparticles, d) PLB 16-5 to PTX/AOT/PLB 16-5/Hep
nanoparticles. Lower row: 1 - nanoparticles, 2- total experimental, 3 - calculated
Table 5.2: Amounts o f polyelectrolytes needed to compensate (zero) or completely
reverse surface charge of nanoparticles, mg/mg PTX
Coating
step

Layer

1

PLB 16-5

PLL

zero

recharged

zero

recharged

PLB on AOT

0.05

0.26

0.08

0.26

2

Hep on AOT/PLB

0.08

0.27

0.23

0.35

3

PLB on AOT/PLB/Hep

0 .1 1

0.26

-

-

4

Hep on AOT/(PLB/Hep)i .s

0.14

0.27

-

-
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Pinacyanol assay showed fewer negative sites accessible after heparin addition.
Such a small value indicated the negatively charged sites were strongly bound to amine
groups of PLB. Similar to PLB on paclitaxel, 0.27 mg o f Hep per 1 mg o f the PTX
colloid was needed for recharging. A significant amount o f heparin unbound to the
nanoparticles remains in supernatant and forms complexes with PLB 16-5 added on the
third step. In Figure 5.4 c, the number o f negatively charge sites were less than the
previous layer deposition, which indicated less PLB 16-5/Hep complexation. Again, the
decreasing amount o f negatively charged surface indicated the attachment o f polycation.
During LbL assembly, we measured particle size after each deposition layer. A bi-modal
size distribution confirmed the presence o f nanoparticles at ca. 150-200 nm and another
peak for free floating PLB/complexes with ca. 40-70 nm diameter (Figure 5.5). As the
LBL assembly was continued, the peak for complexes decreased. We predict the
complexes were attached to the nanoparticle surface.
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Figure 5.5: DLS distribution o f apparent hydrodynamic diameter o f LbL coated PTX
nanoparticles as prepared. Shell: (PLB16-5/Hep)3 5

65
The amount o f PLB 16-5 and Hep needed to recharge the surface in the 1st - 3rd
step and 2nd - 4th step is nearly constant during further LBL assembly (Table 5.2). During
all further experiments, each layer was deposited by a one shot addition o f
polyelectrolytes with the exact amount as determined before to provide “recharging” and
to minimize PLB/heparin complex formation apart the nanoparticles’ surface. LbL
assembly with alteration o f non-PEGylated polylysine and heparin (Figure 5.6) showed
higher amounts negative polyelectrolytes on each step as compared with PLB 16-5.
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Figure 5.6: Changes o f ^-potential (upper row) and amounts of negative sites estimated
by the pinacyanol assay (lower row) in the process of step-wise addition o f a) PLL to
PTX/AOT cores, b) Hep to PTX/AOT/PLL nanoparticles. Lower row: 1 - nanoparticles,
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For the second assembly step o f coating with anionic heparin, pinacyanol assay
showed a lesser amount of negative sites accessible after heparin addition. Such a small
value indicated the negatively charged sites were strongly bound to amine groups o f PLB
(Appendix B). 0.35 mg o f heparin per 1 mg o f paclitaxel was needed to recharge the
surface (Table 5.2). This difference could be observed due to various conformation o f
PEG polymer chains (helix or coil) [102,103].
5.3.4

PVP Influence
As mentioned before, PVP was added to the nanocores preparation as a stabilizing

agent. Stable nanoparticles were formed in the presence of PVP at a concentration o f 2.7
mg/mL. To evaluate the influence o f PVP during the nanoparticles preparation, we
carried out two bilayers o f LbL assembly in the presence o f different concentrations o f
PVP. For each concentration of PVP, the amount o f polyelectrolytes required to recharge
the nanoparticles was calculated. The concentration of PVP up to 7 mg/mL does not
affect the PLB 16-5/Hep multilayer assembly (Figure 5.7).
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Figure 5.7: Influence o f PVP concentration on amounts o f PLB16-5 (1, 3) and Hep (2, 4)
added to reverse the (^-potential of nanoparticles. The polyelectrolytes were added in the
following orders: 1-2-3-4
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5.3.5

LbL Shell Building-up
Each layer deposition during LbL assembly was confirmed using an alteration of

(^-potential measurements (Figure 5.8 a). A deposition o f PLB 16-5 excels over PLL in
order to minimize nanoparticle aggregation during the coating process at a concentrated
dispersion o f about 2 mg/mL. The shifting o f particle size between PLL and PLB, as
positive components, and heparin, as a negative component, using titration can be seen in
Figure 5.8 b. In the case o f non-PEG modified PLL polyelectrolyte, a quick aggregation
was observed as soon as the surface potential lowered the stability limit.
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Figure 5.8: (a) ^-potential and (b) apparent hydrodynamic diameter o f PXT nanoparticles
in the process o f shell assembly. Shell: non-PEGylated (PLL/Hep)4 (1), PEGylated
(PLB16-5/Hep)7.5 (2), and (PLB16-5/Hep)5/(PLB16-5/Hep)2.5 (3)
In the case o f PEGylated nanoparticles, the colloidal stability was sufficient,
which could be a result o f highly hydrophilic PEG tails. So, the electrostatic repulsion of
PEGylated samples was higher than that o f PLL, and it constrained the recrystallization
(Figure 5.9). PLB attachment to AOT sulfate groups was a key factor to preserve
nanoparticle size and the colloidal stability o f a sample.
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For a preliminary understanding o f the LbL assembly based upon PLL and
heparin, we calculated the number of negatively charge sites for the first bilayer. A
similar pattern was confirmed over the LbL assembly during four bilayers (Figure 5.10).
The total amount o f negative sites accessible for pinacyanol increased in dispersion after
the addition o f heparin, and decreased after addition o f PLL solution. The fluctuation in
the total negatively charged sites depicts the same results as a theoretical trend. The
observed difference between experimental and theoretical values, calculated with the
assumption of 1:1 negative to positive sites binding and full ionization o f both
polyelectrolytes, can be explained by a lower degree o f ionization o f polyelectrolytes and
a different stoichiometry o f PLL/Hep binding (Apppendix B). On TEM images (Figure
5.3), each paclitaxel nanocrystal is surrounded by a halo o f less dense material, which can
be recognized as a polyelectrolyte shell of 10-15 nm thickness. In addition, 10-20 nm
polyelectrolyte globular complexes were visible on the surface. A top-view SEM image
confirms amorphous coating on 50-250 nm paclitaxel particles.
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Figure 5.10: Changes o f available sites on nanoparticles surface (grey bar), total (white
bar), and calculated (black bar) amounts o f negative sites in the coating o f a PTX
dispersion as estimated by the pinacyanol assay
On laser confocal images (Figure 5.3), the paclitaxel nanocapsules prepared with
fluorescein-labelled BSA look like well dispersed ca. 300 nm bright spots. This observed
larger particle dimension is due to instrumental function determined by convolution o f
smaller real particle size and resolution o f the confocal microscope, which is ca. 300 nm.
A point o f view exists that FITC can promote adsorption o f FITC-labelled proteins [57].
To spatially separate the core and FITC-bearing polymer, the 3rd and 5th polycation layers
in the shell o f complex (PLB16-5/Hep)s/(PLB16-20/Hep)2.5 architecture were replaced
with PLL-FITC. A high fluorescence o f nanoparticles (corresponding to ~0.10 mg PLLFITC per 1 mg PTX) confirms the attachment o f the fluorescent polyaminoacid to the
shell that covers the nanoparticle surface. The drug loading in 200 nm LbL-coated
nanoparticles, separated from supernatant and lyophilized, was 60-70 wt % for a
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(PLB16-5/Hep)3 5 coating and 30-45 wt % for longer PEG-chain (PLB16-20/BSA)2.5
coating.
5.3.6

Nanocapsule Shell Architecture and Dispersion Stability
An important requirement for intravenous drug nanoparticle formulations is a

diameter o f about 200 nm. Several polyelectrolytes o f natural source, such as hyaluronic
acid, chondroitin sulfate, and dextran sulphate, were not chosen for LbL assembly
because their high molecular weight was too large. These polyelectrolytes do not allow
the desired particle size of 200 nm. Each polymer selection depends on its approximate
length to form a single loop around the particle and to minimize bridging between
neighbour particles [104-106]. Abraxane®, a commercial product o f paclitaxel
formulations consists o f albumin as a key molecule to stabilize the particles. We
developed shell composition by incorporating BSA and FITC-labeled BSA separately as
the anionic component with PLB, which were the most stable in PBS buffer among the
multiple capsule wall architectures (Figure 5.11).
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Figure 5.11: Changes of C,- potential (a) and hydrodynamic diameter (b) in the process of
LbL assembly using BSA. Shell architecture is shown on the graphs
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The 170-190 nm colloids coated with a (PLB16-20/BSA)2 5 shell did not show
signs o f aggregation for 240 hours. Colloidal stability of concentrated paclitaxel LbLnanocapsules in PBS was improved when PLB 16-5 was the copolymer and the shell
architecture was (PLB/heparin)n, n= 3.5-7.5, so that more than ju st the outermost layer
included the PEGylated polyelectrolyte. PEGylated and non-PEGylated polylysine can be
combined in the same shell. Without losing sample colloidal stability, one PLL layer can
be introduced at any location in the shell wall, except the first one. More PLL layers can
be included in a shell if they are separated by at least one PLB/Hep bilayer (Figure 5.12).
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Figure 5.12: Changes o f hydrodynamic diameter in the process o f LbL assembly o f
shells with different architecture using non-PEGylated and PEGylated polylysines
The long-term stability o f LbL shells with an outermost coating o f a grafted PLLPEG, such as PLG65[4.5]5 or PLG20[3.3]2, was low (48-72 hours). These less flexible
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highly PEGylated polyelectrolytes provide only a limited number o f charged groups per
chain length, and their cooperative binding to the nanoparticle surface is low.
To evaluate the complications caused by possible nanoparticle aggregation in
blood upon intravenous injection, the colloidal stability o f LbL-coated nanoparticles in
fetal bovine serum was tested. In serum, paclitaxel nanoparticles coated with (PLB 165

/Heparin)3.5 shell or having one more negatively charged polyelectrolyte layer as the

outermost layer retains a size below 250 nm for at least 24 hours.
5.3.7

Enhancing o f PEG Modification o f Polvelectrolvte Shell
PTX nanocapsules with a (PLB16-5/Hep)s 5 shell (with PLB 16-5 as the outermost

layer) have ca. —0.5 pmol of -N H 2 groups per 1 mg PTX. At the lowest mPEG 5kDaSVA concentration o f 10 mg/mL, the molar amount o f PEGylator is twice the number of
-NH 2 groups on the surface o f the nanocapsules. With the excessive amount of
PEGylator, about 30% o f amine groups interact with 5kDa PEG (T able 5.3).

Table 5.3: Amount o f amine groups on the surface o f PTX nanocapsules before and after
PEGylation
PEGylation

Amount NH2 groups (in mg
PLB 16-5 /mg PTX)

C (mPEG-SVA),
mg/mL
0

unPEGylated
5kDa
5kDa

Decrease,
%

PLB16-5/Hep)55
0.099
0.069
0.056

0
10
250

30
44

(1PLB16-5/Hep)75
-

unPEGylated
5kDa

0
50

0.120
0.068; 0.094

43; 21

20kDa

100

0.108; 0.114

9.7; 5.0
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The maximum increase o f PEGylated sites reaches 40% o f available free amine
groups at the highest mPEG5kDa-SVA concentration. The 5kDa PEGylator reacts with a
larger number o f amine groups on the surface than the corresponding 20 kDa derivative.
The less interaction o f mPEG20kDa-SVA is due to bulk 20kDa tails and the high
viscosity o f the solution.

5.3.8

OCM Evaluation o f PEGylated and Non-PEGvlated Film Thickness.
Viscoelasticity and Protein Adsorption Resistance
Additional data on LbL assembly o f block-copolymers o f PEG and polylysine

with heparin were obtained with the QCM-R technique. A decrease o f resonance
frequency AF and an increase o f equivalent resistance AR during the LbL assembly on
the resonator surface provide evidence o f a step-wise growth o f the film (Figure 5.13).
AR is not the electrical resistance o f the film, but it is an independent measurement for
viscosity and density o f the liquid and film in the vicinity o f the resonator surface. Af
depends upon the adsorbed rigid mass as well as the viscosity and density o f the deposit
and solution in the vicinity o f the crystal-liquid interface [74,75].

74

—
iu O *0
to o

100

O. X

a

a:
<i

cl

o JS Q

X

AR

50

n

rsi

-50
ll

AF

<1

-100

-150
0

2000

6000

4000

8000

Time, s

Figure 5.13: Af and AR o f a 5 MHz resonator in the process o f adsorption of a (PLB 1620/Hep)3.5 film and FBS protein adhesion resistance testing

The equal increments o f AF and AR for a bilayer adsorption from 0.1 and 0.5
mg/mL polyelectrolyte solutions indicate that both concentrations assure the saturation of
the adsorbed polyelectrolyte layers at every deposition cycle. On a single step o f non
washing assembly, each polyelectrolyte is added in the amount that corresponds to its 0.1
mg/mL concentration in the nanoparticles dispersion. It is sufficient to form a saturated
layer o f the polyelectrolyte on the surface o f the nanoparticles.
When calculated assuming the formation o f rigid films, the thicknesses o f wet
polycation/heparin layers formed with PLB and PLL are almost the same [17,107]. A
slightly higher value for PLB 16-20/Hep bilayer can be related to the presence of longer
upstanding PEG tails. The value o f AR, which characterizes the energy dissipated during
resonator vibration due to an inelastic film on its surface, is higher for a PLB 16-20/Hep
containing longer PEG than that for PLB 16-5/Hep. The thickness and viscoelastic
properties o f a PLL-based bilayer are comparable to those for PEGylated
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polyelectrolytes. Presumably, due to different chain conformation, PLL forms slightly
thicker layers with rougher surfaces that impact film properties. For example, a larger
amount o f polyelectrolytes are needed to reverse the surface charge o f nanoparticles, if
PLL is used for coating (Table 5.2).
5.3.9

Influence o f PEGylation on Serum Protein Adsorption
The AF and AR values o f resonators modified with LbL film and brought in

contact with a 40 mg/mL BSA or serum are changing due to both the higher viscosity of
the media and protein adsorption on the film surface (T able 5.4). The LbL-films on the
basis o f PEGylated polylysine have better resistance to BSA adsorption than those of
PLL, and a (PLB16-20/Hep)3.5 coating repels albumin better than the other compositions.
This is in agreement with commonly accepted point o f view on the role o f PEG surface
modification in increased protein adsorption resistance [102,103].

Table 5.4: AF and AR for a resonator with a (Polycation/Hep)3 .s film exposed to BSA and
serum
-AF, Hz; AR, f i
Polycation

c,
mg/mL

PLL
PLB 16-5

0.1
0.1
0.5
0.1
0.5

PLB 16-20

In contact with
BSA
103; 30.9
84; 27.9
62; 25.3

FBS
103; 21.6
110; 20.4
109; 24.8
132; 7.3
77; 33.0

Rinsed with water
BSA
24; 0.6
13; 0.0
9;-0.5

FBS
60; -8.5
100; -19.7
40; -2.3
132; -12.5
28;-16.1
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On the contrary, much larger AF and AR for a resonator immersed in serum and
rinsed with water indicate a significant adsorption of serum proteins on all
polycation/heparin films. Serum is rich in small globular proteins that can penetrate
through a rather loose brush o f PEG-tails on the film surface. Moreover, globulins have a
certain affinity towards PEG moieties that can promote their interaction [42]. There is a
decrease in FBS protein adsorption on (PLB/Hep) 3 .s films formed from more
concentrated (0.5 mg/mL) polyelectrolyte solutions, as compared with the lower
concentration. The PEG surface density o f such films can be higher, although there is no
difference between the calculated characteristics o f the films. A negative shift o f AR in
water after FBS protein adsorption can be explained by a decreasing surface roughness or
facilitating o f surface sliding friction by the adsorbed proteins [75,76]. The LbL assembly
of PLB 16-5 and Hep was confirmed by QCM and the mass of the 4.5 and 7.5 films were
calculated (Table 5.5). The mass o f PEG20kDa attached to the film is ~ 1.2-1.7 times
exceeding that o f PEG5kDa. The difference between 4.5 and 7.5 films in enhanced PEG
amount is negligible. Therefore, we assumed the maximum possible PEGylation degree
that corresponds to the surface coverage by PEG tails depends on the amine groups
available at the outermost surface. Despite many amine groups remaining unreacted on
the surface, further PEG attachment was hindered by neighboring PEG tails. This last fact
is supported based on the evaluation o f the amounts o f amine groups on the PTX
nanoparticle surface. The adsorption o f mPEG-SVA did not destroy the PLB 16-5/Hep
film. The attachment o f serum proteins was decreased significantly due to enhanced
PEGylation. The AF shift which is proportional to the deposited mass is 5-11 Hz for
PEGylated surfaces vs. 30-130 Hz for the surfaces without enhanced PEGylation. The
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attachment o f serum proteins was comparable for 5kDa and 20kDa mPEG-SVA. The
mass o f the attached PEG depends on the concentration o f PEGylator used (Table 5.6).
The mPEG5kDa-SVA concentration o f 5 mg/mL provides ~ 50% less PEG attached to a
7.5 PLB 16-5/Hep LbL film than a 50 mg/mL concentration. The PEG coating obtained at
5 mg/mL concentration o f mPEG5kDa-SVA was not sufficient to efficiently resist
adsorption o f proteins from fetal bovine serum.

Table 5.5: PLB 16-5/Hep thinkness, amount o f attached PEG, and binding o f serum
proteins on modified polyelectrolyte films
dF, Hz
Bilayers
Mass, pg/cm2
Mass o f deposited film
PLB 16-5/Hep
7.5
51.2±10.7
0.9±0.2
4.5
35.0±5.6
0.6±0.1
Amount of attachec PEGylator, C (mPEG-SVA)=50 mg/mL
7.5
PEG 5kDa
41.1+7.3
0.7±0.1
4.5
49.4±16.1
0.9±0.3
PEG 20kDa
7.5
70.3
1.2
4.5
58.0
1.0
Serum protein attachment
PEG 5kDa
7.5
5.7
0.1
PEG 20kDa
11.0
0.2
4.5
PEG 5kDa
4.7±4.2
0.1
PEG 20kDa
11.0
0.2
Assembly

Table 5.6: Influence o f PEGylator concentration on the amount o f PEG attached and
serum protein adsorption on (PLB16-5/Hep)7.s LbL films

C(mPEG5kDa-S V A),
mg/mL
50
5

PEGylation
mass,
pg/cm2
dF, Hz
0.7+0.1
41.1±7.3
22.0
0.39

Serum protein adsorption
mass,
pg/cm2
dF, Hz
0.1
5.7
2.2
122.6
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5.3.10 Influence o f LbL Shells on Release o f Paclitaxel
Paclitaxel possesses an extremely low solubility in aqueous solutions (5.6 mg/L
for PTX) and without a solubility enhancer their released concentrations are difficult to
monitor [96-98], For all tested PTX colloids, a fast initial dissolution (more than 20%) of
the drug was observed within fifteen minutes after the addition o f the nanoparticles to a
0.2 mg/mL Polysorbate 80 release medium. The rest o f the drug was released very
slowly; a complete dissolution of the nanoparticles was observed within 65-70 hours
(Figure 5.14).
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Figure 5.14: PTX release from 300 nm nanoparticles prepared using top-down sonication
assisted LbL method and coated with a (PLL/Hep)n shell. Number o f bilayer in shell, n:
1- 0.5,2-4, 3-8,4-12. 0.2% Polysorbate 80 in water at 37 °C
5.4

Conclusion

We prepared stable nanocolloids o f paclitaxel particles o f about 150-200 nm size
using washless LbL assembly of (PLB16-5/Hep)7 5 . The concentration of the
nanoparticles was 2-3 mg/mL, which was stable for up to a few weeks. The washless LbL

assembly helps to improve efficiency o f the entire process, to preserve the amount of
polyelectrolytes, and to avoid aggregation due to the usual washing steps involving the
LbL assembly technique. LbL-coated nanoparticle surfaces were modified with PEG
moieties to avoid serum protein adsorption. Variations in the number of bilayers on the
nanoparticle surface were beneficial for the controlled release o f paclitaxel.
In the next chapter, the safety and tolerability o f particles coated with (PLB 165/Hep)7.5 is determined in an in vivo study. The effects of PEG modification is analyzed
using a cancer cell line for the in vitro study. Depending on the result o f the previous in
vitro study, the particles are modified further for targeting therapy.

CHAPTER 6

PACLITAXEL NANOPARTICLES FOR TARGETED DELIVERY

6.1

Introduction

Parts o f the following in vivo and in vitro studies were done in collaboration with
Dr. Torchilin’s laboratory at Northeastern University, Boston, USA. The preparation of
stable paclitaxel nanocolloids was optimized, in participation with the collaborator, with
the aid o f the in vivo and in vitro results.
An optimization o f injectable 150-180 nm capsules was formed with a core of a
poorly soluble drug, such as paclitaxel, and a shell composed o f 3-8 bilayers of
biodegradable polyelectrolytes. In previous chapters, we used various nanocapsule shell
compositions and aggregation-free preparation techniques to produce stable colloids, and
to reduce the amount o f serum proteins adsorption on the nanoparticle surfaces. The
overall objective is to couple monoclonal antibodies 2C5, for nucleosome specificity,
with LbL-coated nanocapsules, and thus to increase the accumulation o f the drug in
tumor cells [108].
In this chapter we prepared gelatin nanoparticles o f 200-220 nm size, which were
considered as paclitaxel nanocores for further analysis. Gelatin nanoparticles are
reproducible and they allowed for easy fluorescent labeling for future studies. The
nanoparticles were coated with a shell composition o f (PLB 16-5/Hep) under the same
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experimental conditions. Gelatin nanoparticles were modified with the enhanced
PEGylation method and used for the in vitro studies. The conditions o f the carbodiimidemediated coupling method on gelatin nanoparticles was optimized to preserve the activity
of the 2C5 antibody [109]. The paclitaxel nanocores were fluorescently labeled through
the formation o f lipid-fluorescent molecule complexes. An attempt at synthesizing a
smaller particle size (less than 100 nm) was carried out using lipids.

6.2
6.2.1

Materials and Methods

Materials
Most o f the reagents for LbL assembly are already listed in the previous chapter.

In addition, we received l,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N[methoxy(polyethylene glycol)-2000] (ammonium salt) (PEG2kDa-PE), rhodamine
conjugated PE (PE-Rhod) and monoclonal antibodies 2C5 from Dr. Torchilin’s
laboratory, Northeestem University, USA. Bovine IgG was received from Equitech-Bio
Inc. USA. Methoxy polyethylene glycol-succinimidyl valerate, M W 5000 (mPEG5kDaSVA) and mPEG20kDa- SVA (MW 20,000) were received from Laysan Bio, USA.

6.2.2Gelatin-Rhodamine Nanoparticles
Gelatin nanoparticles were produced from gelatine, type A by a two-step
desolvation procedure, as described in Appendix B [110]. The average size o f the
nanoparticles in different batches was between 200 to 220 nm in PBS. The nanoparticles
were labeled with Rhod G -isothiocyanate (RITC) by mixing 15 mL of nanoparticles
dispersion at a concentration o f about 2.0 mg/mL and 0.3 mL o f 1 mg/mL RITC solution
in water. The mixture was stirred for 4 hours at room temperature in the dark. The gelatin
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nanoparticles labelled with Rhod G (Gel-Rhod) were separated from supernatant by
centrifugation at 7,000 rpm for twenty minutes. The nanoparticles were redispersed in
PBS, separated by centrifugation a second time, and finally redispersed in 25 mL o f PBS.
The LbL shell comprising 7.5 bilayers o f PLB 16-5/Hep was formed on 20 mL o f GelRhod nanoparticles in PBS by sequential addition o f PLB 16-5 and Hep. Each layer was
deposited by the addition o f 30 pL from polyelectrolyte solution at a concentration o f 60
mg/mL. The amounts o f polyelectrolytes needed for charge reversal were found
experimentally as done previously for drug nanoparticles. The final diameter o f the
nanoparticles was measured using the C,- potential analyser.
To enhance PEGylation o f the existing polyelectrolyte shell, mPEG5kDa-SVA or
mPEG20kDa-SVA at a concentration o f 0.25 mg/mL was added to 6 mL o f Gel-Rhod
coated with 7.5 bilayer o f PLB 16-5/Hep and kept for 12 hours in the dark at +4 °C. The
nanoparticles were separated by centrifugation at 7,000 rpm for twenty minutes, washed
once with PBS, and finally redispersed in ~1.0 mL of PBS. The amount o f Rhod G
attached to the nanoparticles was calculated by measuring free Rhod G in the supernatant.
A cancer cell line, 4T1, was studied for the amount o f uptake o f gel-Rhod particles with
different shell compositions. In vitro analysis o f gel-Rhod uptake was done at 37 °C and
20 °C. For cell testing, all samples were diluted with PBS to equal fluorescence intensity,
which was close to a concentration o f 4 pg/mL.
6.2.3

Modification o f Nanoparticles with Tumor Targeting Proteins
Two approaches were tested for conjugation o f tumor-targeted monoclonal

antibodies,

2C5,

with

LbL-coated

carbodiimide-mediated crosslinking.

nanoparticles:

glutaraldehyde-mediated

and
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6.2.3.1

Glutaraldehvde-mediated conjugation with Ab 2C5
Paclitaxel nanoparticles coated with a (PLB16-5/Hep)75 shell were prepared at a

concentration of 2 mg/mL. Samples that contained 50 pL o f 25 % glutaraldehyde and 1.5
mL o f nanoparticle solution were prepared and incubated for 5 h. The solutions were
centrifuged at 14,000 rpm for ten minutes and redispersed in 1 m L o f PBS. A 2C5
solution was mixed with glutaraldehyde-treated and untreated paclitaxel nanoparticles to
reach a final concentration of 2 mg/mL. The ratio of paclitaxel nanoparticles to 2C5 was
kept at about 2:1. Each mixture was incubated for 12 hours at room temperature,
separated by centrifugation at 14,000 rpm for ten minutes and redispersed in 1 mL of
PBS at pH 7.2 [109].
6.2.3.2

Carbodiimide-mediatedconjugation with IsG
We compared three different ways o f IgG conjugation to paclitaxel nanoparticles,

one-step and two-step EDC-sulpho-NHS mediated methods and adsorption. The one-step
and two-step methods o f EDC-sulpho-NHS conjugation with and without quenching o f
EDC by mercaptoethanol are described in the previous work [109].
For each sample, 1.6 mg/mL IgG-Rhod was mixed with 0.3 mL o f paclitaxel
nanoparticles at a concentration o f 0.4 mg/mL. For the adsorption technique, a neagative
control was mixed without crosslinking agents. For one step conjugation, the conjugation
reagents were mixed with IgG-Rhod and paclitaxel nanoparticles. For the two-step EDC
plus Sulpho-NHS conjugation, the same amount o f IgG-Rhod w as activated with 20 pL
o f 1.0 M EDC and 55 pL o f 0.1 M sulpho-NHS one-by-one for fifteen minutes at room
temperature. For EDC quenching, 20 pL o f 1.11 M mercaptoethanol was added to
deactivate EDC. All the samples were kept at room temperature for three hours. After
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incubation o f the IgG-Rhod conjugation, the nanoparticles were separated by
centrifugation at 9,000 rpm for ten minutes and redispersed in 0.2 mL PBS buffer. The C,potential analyzer was used to measure the ^-potential and nanoparticle size.
To optimize the carbodiimide conjugation method, bovine IgG was used in
several experiments. UV-vis spectroscopy was used to analyze the amount o f IgG bound
to the nanoparticles. In order to enhance detection sensitivity, IgG was preliminarily
labeled with Rhodamine isothiocyanate (RITC), as indicated by Harlow and Lane [111].
IgG-Rhod have a ratio o f absorbance at 558/278 nm o f 0.18±0.01, which was used to
recalculate the concentration o f IgG attached to the nanocapsules. The amount of
paclitaxel in the dispersion was estimated using UV-Vis, as mentioned in Chapter 4.
6.2.3.3

Influence o f crosslinkins asents
A set o f experiment was designed to understand the effects o f the sequence of

reagent addition and the amount o f crosslinking agents on IgG-Rhod conjugation to the
nanoparticle surfaces. Two samples of nanoparticles were coated with 7.5 and 8 bilayers
o f PLB 16-5/Hep, respectively. For nanoparticles coated with 8 bilayers, nanoparticles
were considered as the carboxylic component (free carboxylic groups in Hep) and
antibodies as the amine component in the crosslinking pair. For nanoparticles coated with
7.5 bilayers, IgG-Rhod was considered as the carboxylic component (free amine groups
in PLB) and antibodies as carboxylic component in the crosslinking pair. For each
reaction, the carboxylic components were treated with EDC/sulfo-NHS, and the free
EDC in the solution was quenched with mercaptoethanol. Finally, the respective amine
component of the crosslinking pair was added to the reaction and incubated for three
hours at room tempearature. The molar ratio o f EDC/sulfo-NHS/mercapto-derivative in
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the reaction mixture was kept constant at 1:0.275:1.11. The ratio between the
concentrations o f IgG-Rhod to the concentration o f PTX in the reaction mixtures was
about 2.3 mg/mg. After the reaction, the nanoparticles with attached IgG-Rhod were
separated from supernatant by centrifugation at 10,000 rpm for ten minutes and
redispersed in 1 mL o f PBS. A UV-Vis spectraphotometer was used to determine the
amount o f paclitaxel and IgG-Rhod.
6.2.3.4

Carbodiimide-mediated conjugation with 2C5
PTX-Rhod(PE) nanocores were prepared by adding 30 pg/mL o f Rhod(PE) at

preparation time along with surfactants. In these experiments, the usual paclitaxel
nanoparticles were used as the control. Each sample was divided into equal aliquots and
coated with 7.5 or 8 (PLB 16-5/Hep) bilayers in PBS buffer, respectively. The
experiments were similar to the IgG conjugation in the experiments described in the
previous section, except that the ratio o f the concentration o f 2C5 to the concentration of
PTX-PE in the reaction mixtures was about 1.1 mg/mg, and additional control samples
with amine and carboxylic components were added. To estimate the amount o f 2C5
antibodies on the nanoparticles, the nanocapsules were dissolved in ethanol and
absorbance was measured at a wavelength o f 300 nm. The usual 2C5 absorption
wavelength is 280 nm, but paclitaxel concentration affected the same wavelength. The
concentration o f PTX in the samples was measured using the UV-Vis spectrophotometer.
6.2.4

In Vivo Studies
Twenty four female mice from BALB/c were used. The mice were aged between

five to six weeks at the beginning o f the experiment. Paclitaxel nanoparticles coated with
(PLB16-5/Hep)7.5 at concentrations o f 20 and 40 mg o f paclitaxel per kilogram of mice
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weight was injected into the tail vein. Plasma drug concentration was measured at several
points in time. For each sample, three mice were injected with the specified
concentration.

6.3
6.3.1

Results

Gelatin-Rhod Nanoparticles
Gelatin nanoparticles with a diameter o f -2 0 0 nm were prepared for further in

vitro study and conjugation method. The nanoparticles were diluted to a concentration of
1 mg/mL using PBS and distilled water. The nanoparticles size was measured using a £hydrodynamic particle size analyzer at 24 hours intervals for up to four days. The
nanoparticles were stable in PBS solution (Figure 6.1).
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Figure 6.1: Stability o f gelatin nanoparticles in PBS and distilled water
Gelatin nanoparticles were labeled with RITC without changing their particle
size. Gel-Rhod was coated in PBS similar to paclitaxel nanocores using LbL assembly for
further in vitro study. The amounts o f polyelectrolytes needed for charge reversal were
found experimentally similar to paclitaxel nanoparticles. The final diameter of
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nanoparticles coated with 7.5 bilayers o f PLB 16-5/heparin was 228±20 nm, ^-potential
+23.8±2.5 mV (Figure 6.2).
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Figure 6.2: Particle size and ^-potential o f gelatin nanoparticles during LbL assembly
based upon coatings o f (PLB16-5/heparin)7.5
Gelatin nanoparticles were aggregated during LbL assembly based upon
unPEGylated polyelectrolytes PLL/Hep. A similar tendency o f gelatin nanoparticles was
observed with PTX nanoparticles during LbL assembly. The gelatin nanoparticles, coated
with 7.5 bilayers o f (PLB 16-5/Hep), with Hep on the top did not aggregate in PBS for 7
days. Gel-Rhod particles coated with (PLB16-5/Hep)7.5 were coated with excess PEG
molecules using different molecular weights o f mPEG-SVA. The particle size did not
change significantly after enhanced PEGylation. Gel-Rhod particles with different shell
compositions were normalized to detectable fluorescence intensity and added to the
fibroblast cell line, 4T1. Uptake o f gel-Rhod particles by the cells were separated using
fluorescence activated cell sorting technique.
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The geometric mean of fluorescence intensity was measured as the average
number o f cells, which was the total amount o f rhodamine conjugated on the gelatin
nanoparticles. The geometric mean pattern across all different samples was found to be
similar to that for cells at 20 °C and 37 °C. In support o f the QCM results, fewer mPEGSVA-coated gel-Rhod particles bound to 4T1 cells than did uncoated or only LbL coated
gel-Rhod particles. Gel-Rhod with mPEG20k-SVA showed the maximum resistance to
cell binding. Thus, the particles with excess PEG molecules need to be conjugated with
antibodies in order to attain specific targeting towards tumor cells (Figure 6.3).
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Figure 6.3: Amount o f gelatin-rhodamine particles binding to 4T1 cells, 1- uncoated
gelatin-rhod, 2- gel-rhod- (PLB16-5/Hep)7.s, 3 - gel-rhod-(PLB16-5/Hep)7.5- (PEG5kDaSVA), and 4 - gel-rhod-(PLB16-5/Hep)75- (PEG20kDa-SVA)
6.3.2

Glutaraldehvde- mediated Conjugation o f 2C5 Antibodies to Paclitaxel
Nanoparticles
The average particle size o f paclitaxel-coated 7.5 bilayers o f PLB16-5/PLB was

about 230 nm. Particle size of glutaraldehyde-treated paclitaxel nanocapsules was
increased significantly after 2C5 attachment. More than 50% o f the nanoparticles were
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found to have a diameter higher than 700 nm. Whereas untreated nanoparticles with
adsorption o f 2C5 antibodies were found to have a diameter size o f 270 nm. ELISA
studies showed that glutaraldehyde-treated nanoparticles possessed a higher amount o f
2C5. The increase in particle diameter eliminated glutaraldehyde-mediated 2C5
conjugation as a reliable method, despite the technique’s ability to conjugate 2C5
antibodies.
6.3.3

Influence of Crosslinking Agents on Targeted Nanoparticles
The first objective was to optimize the steps necessary for IgG-Rhod conjugation

to LbL-coated paclitaxel nanoparticles. Different ways o f conjugating IgG on paclitaxel
particles are summarized below (Table 6.1). A two-step method with quenching o f EDC
by mercaptoethanol produced a higher degree o f conjugation than the other methods.
Also, IgG conjugation increased the nanoparticle size. We believe the size o f the particle
can be decreased by optimizing the amounts of crosslinking agents and antibodies. For
EDC/sulfo-NHS crosslinking reaction, the amount o f IgG-Rhod per 1 mg PTX
nanoparticles was decreased, as compared with direct adsorption. However, changes in
either the EDC/sulfo-NHS concentrations or the order o f the addition o f the reagents did
not influence the amount o f IgG-Rhod attached to nanoparticles (Figure 6.4). The order
of mixing IgG-Rhod and LbL coated PTX nanoparticles was carried out as carboxylic
component and amine component, respectively and vice versa. Both sequences o f
crosslinking methods did not influence the amount o f IgG-Rhod attached to
nanoparticles. The amount o f IgG-Rhod conjugated with PTX nanoparticles was ~1±0.1
mg per 1 mg PTX.
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Table 6.1: A list o f methods for optimization o f IgG conjugation to LbL coated PTX
nanoparticles
Method
No treatment
adsorption
One-step conjugation
Two step without quenching
o f EDC
Two step with mercapto
ethanol quenching o f EDC

C(IgG-Rhod)/C(PTX),
mg/mg
0
0.21
0.29

Diameter,
nm
142.8 ± 12
338.5 ± 3 2
240.5 ±24

^-potential,
mV
+25±3
+23±2
-12±9

0.11

197.7 ± 40

-22±7

0.97

326.5 ± 12

-6±2

2
1.8
1.6

1.4
1.2

1
0.8
0.6
0.4
0.2

Miseries 1
♦ series 2

0
0

0.01

0.03
C (E D C ), M

0.02

0.04

0 05

Figure 6.4: Dependence o f the IgG-Rhod/PTX ratio on concentration of EDC, series 1 PTX nanoparticles as carboxylic component and series 2- IgG-Rhod as amine component
6.3.4

Carbodiimide-mediated Conjugation o f 2C5 Antibodies
After optimizing carbodiimide-mediated conjugation of IgG-Rhod on paclitaxel

particles, we carried out the same protocol for conjugation o f 2C5 antibodies to decide
the sequence o f the addition o f reagents. Since fluorescent labeling to paclitaxel was not
possible by any method, we labeled paclitaxel cores using Rhodamine-labeled PE (as
lipid), followed by LbL assembly. Four samples with different sequences o f carboxylic
and amine components were prepared for ELISA analysis and in vivo study (Table 6.2:
Characteristics o f PTX and PTX-Rhod(PE) nanoparticles before and after conjugation
with 2C5 antibodies)
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Table 6.2: Characteristics o f PTX and PTX-Rhod(PE) nanoparticles before and after
conjugation with 2C5 antibodies
Sample
PTX/(PLB165/Hep)7.5/2C5
PTX/(PLB165/Hep)8/2C5
PTXRhod(PE)/(PLB 1
6-5/Hep)7.5/2C5
PTXRhod(PE)/(PLBl
6-5/Hep)8/2C5

Carboxylic
component

C(PTX),
mg/mL

(2C5),
g/mL

C(2C5)/
C(PTX), mg/mg

Diameter
, nm

2C5

2.44

0.48

0.18

232±16

nanoparticle

1.61

0.61

0.14

232±7

2C5

1.40

0.37

0.21

260±14

nanoparticle

1.31

0.37

0.23

283+13

Initially, an ELISA study was done to confirm the activity o f 2C5 antibodies
conjugated to PTX nanocapsules. From the study, PTX nanoparticles coated with eight
bilayers retained the highest amount o f 2C5 antibodies after conjugation (S2 and S4 in
Figure 6.5). Although the sequence of reagents addition did not affect IgG-Rhod
antibody conjugation, 2C5 antibodies conjugation was observed for the sequences with
PTX nanoparticles as a carboxylic component.

0.2
Cl
S4

0.15

0.1
S3

SI

0.05

O
0.02

0.2
2
Coaceatratioa o f 2C5, ^ig/aiL

20

Figure 6.5: ELISA analysis o f PTX nanoparticles conjugated with and without 2C5, C l2C5 antibodies, SI - PTX/(PLB16-5/Hep)7.5/2C5, S2- PTX/(PLB16-5/Hep)8/2C5, S3PTX-Rhod(PE)/(PLB 16-5/Hep)7.5/2C5, and S4 - PTX-Rhod(PE)/(PLB16-5/Hep)8/2C5
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For the in vivo study, we chose PTX-Rhod(PE) nanoparticles coated with 7.5 and
8 bilayers o f PLB 16-5/Hep as controls (Figure 6.6). In addition the same nanoparticles
conjugated with 2C5 antibodies were analyzed for cell uptake. The Geo Mean o f the
fluorescence intensity was measured as the average number o f cells, which was
proportional to the PTX-Rhod(PE). The geometric mean values indicated the maximum
number o f cells PTX-Rhod(PE) coated with eight bilayers o f PLB 16-5/Hep and
conjugation with 2C5.

Coatrob

witk 2C5

Figure 6.6: Amount o f PTX-Rhod(PE) particles binding to 4T1 cancer cells
6.3.5

In Vivo Studies
The survival o f mice after intravenous administration was determined to assess

the safety and tolerability o f paclitaxel nanoparticles. The plasma drug concentration was
found to be ten times less than commercially available formulation, Taxol® (Figure 6.7).
Further adsorption o f excess PEG molecules on LbL-coated nanoparticles using mPEGSVA may increase the circulation time o f the nanoparticles.
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Figure 6.7: Plasma drug concentration o f mice injected with paclitaxel nanoparticles
(statistical data based upon n = 3)

CHAPTER 7

CONCLUSION AND FUTURE W O R K

7.1

Conclusion

We developed stable colloids o f paclitaxel nanoparticles o f 150-180 nm size that
had a high concentration o f ca. 3 mg/mL in PBS buffer for at least two weeks. The
nanoparticles were prepared based upon the ultrasonication assisted desolvation method
and were then encapsulated with a washless LbL method. The architecture of the LbL
shell composition was developed by pre-determined constituents, including a co-polymer
o f oppositely charged polyelectrolytes. A novelty nanoassembly modification is to coat
nanoparticles ca. 150 nm with a thickness o f about 3-5 nm o f each layer for the desired
features. This work is a significant improvement o f low-solublity drug formulation for
intravenous administration.
Sonication-assisted LbL assembly is a logical development for improving
solubility o f low solublity materials. Our aim is to achieve the dispersion o f stable
nanocolloids o f ca 200 nm, particularly low-solublity anticancer drugs. We developed
this technique for low solublity organic as well as inorganic materials. This versatile
technique has potential applications in several industries, including pharmaceutical,
material composites, anticorrosion agents, and paint industries. The limitations associated
with the ultrasonicator, including admixture o f eroded particles from the sonotrode and
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longer sonication time, are specific new challenges for low solublity anticancer drugs. To
achieve the highest possible concentration o f paclitaxel formulation, our preparation
technique, based on the main goal, is shifted by building strongly charged polyelectrolyte
shells around the ampiphile-stabilized drug cores.
Our successful attempt to prepare stable nanoparticles is based on the desolvation
method with LbL assembly under sonication. Numerous key features o f the technique
make it attractive for further advancement. First, washless LbL assembly avoids the
traditional centrifugation-based washing steps and retains stabilizers for nanocores
formation. Also, the amounts o f samples and polyelectrolytes are conserved efficiently.
Second, the low molecular weight o f the block-copolymer o f poly-L-lysine with
polyethylene glycol (PEG) helps to improve the stability o f nanoparticles for better shelflife. Also the excess PEG molecules help to decrease the serum protein adsorption, which
is a necessary step for extending the circulation time o f the nanoparticles. The number of
layers can be modified for the controlled release o f the drug. Fourth, further modification
o f the nanoparticle shell architecture using targeted biomolecules, such as monoclonal
antibodies 2C5, has been shown to be desirable for its effectiveness under in vitro studies.
In vivo studies provide the preliminary confirmation o f biocompability and safety of
paclitaxel nanoparticles at a concentration o f 20 mg of PTX per 1 kg o f body weight for
mice.

7.2

Future Work

Our results indicate a successful approach for low-solublity drug nanoparticle
formulation. Still, the work can be improved by modifying the architectural shell
composition as well as further analysis of the existing nanoparticles. The drug nanocore
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formation can be stabilized using hydrophobic modified polyelectrolytes. Another
alternative for low molecular weight biomolecules, similar to bovine serum albumin,
needs to be complexed for the nanocore formation. Such nanocores can be stabilized to a
higher degree with a comparatively small size.
QCM studies can be extended to understand the antibody’s adsorption to the
established shell composition. The QCM analysis can be helpful to optimize the amount
o f antibodies for conjugation methods. Several shell compositions o f biological sourced
polyelectrolytes can be tested using QCM for resistant to serum protein adsorption.
Further, the least protein absorbing shell composition can be improved with excess PEG
molecules. The in vitro drug release study needs to be analyzed in-detail using bovine
serum albumin. Since the pH o f the tumor microenvironment is acidic, the in vitro drug
release kinetics needs to be analyzed under pH conditions that are similar conditions to
those found in the tumor site. The particle size o f the nanoparticles after antibody
conjugation was increased to 400 nm. An optimization o f crosslinking agents and the
amount o f antibodies can be modified to reach a particle size close to ca. 200 nm.
In vivo analysis o f nanoparticles coated with block-copolymer o f poly-L-lysine
with different molecular weights o f PEG can help to improve the circulation time. Also,
the drug accumulation at the tumor site needs to be compared between the nanoparticles
coated with optimized PEG concentration and further antibodies conjugation. A detailed
analysis o f drug distribution for different organs can improve targeted therapy for better
efficacy. For biodistribution analysis, the shell containing one o f fluorescent labeled
polyelectrolytes can be injected intravenously and further detection o f fluorescent
intensity can be done for drug accumulation at various organs.

APPENDIX A

PACLITAXEL CONCNETRATION CALIBERATION CURVE
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Paclitaxel drug concentration after LbL assembly and during drug release studies
was determined using the following procedure.
1)

Stock solutions o f paclitaxel at concentrations o f 1 mg/mL and 0.1 mg/mL were

prepared using ethanol.
2)

For each measurement, the following specified amount (second column) o f stock

solution was added to 2 mL ethanol (Table A.1).
3)

UV absorbance o f each solution was measured at wavelength o f 228 nm (Figure

A.1)
Table A.1: Mixing ratio o f paclitaxel sample in ethanol for UV-Vis measurements
Stock solution
ofPC T
0.1 mg/mL

1 mg/mL

Amount o f stock solution
added in 2 mL ethanol (pi)
20
40
60
80
100
20
40
60
80
100
120

Final concentration
o f PCL (mg/mL)
0.00099
0.00196
0.00291
0.00385
0.00476

Absorbance at
228 nm
2.53E-02
5.22E-02
8.19E-02
0.11153
0.13638

0.0099
0.01961
0.02913
0.03846
0.04762
0.0566

0.26667
0.69152
1.0204
1.3472
1.5981
1.8512

1.8

1.6
1.4

0.8
06
0.4
0.2
0.02

0.04

0.06

C(PCT), mg/mL

Figure A.1: Standard calibration curve o f paclitaxel concentration in ethanol

APPENDIX B

PINACYANOL ASSAY
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Pinacyanol chloride is a positively charged dye, which shows an absorbance peak
at a wavelength o f 470-480 nm on a UV-Vis spectrophotometer while attached to
negatively charged sites. Pinacyanol dye reacts only with free negative sites, such as
sulphonates and carboxylates. When PLL is added, the number o f available negative
sites decreased. It is interesting that in positively charged samples with PLL on the top or
in solution, there is still a lot of negative sites available for pinacyanol attachment.

B .l

Theoretical Measurement of Negatively Charged Sites in Nanoparticles
Theoretically, the amount of negatively charged sites on paclitaxel cores were

measured based upon the following prior information. Assuming the polymers are fully
charged, 1 mg o f PLB 16-5 corresponds to 4.6 pmol of amine groups. 1 mg of Heparin is
equal to 6.2 pmol (or 4.8 pmol) o f charged groups, if one heparin polymer unit contains
four (or three) charged groups. It gives 1.38 mol/mol (or 1.05 mol/mol) negative to
positive charge binding ratio for Hep on the top o f a PLB 16-5-coated colloid and 0.72
mol/mol (or 0.93 mol/mol) o f PLB 16-5 amine to Heparin negative charges.

APPENDIX C

PREPARATION OF GELATIN NANOPARTICLES
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The two-step disolvation method was carried out for the preparation of gelatin
nanoparticles as shown below.
1)

1.25 g o f gelatin type A was dissolved in 25 mL o f water by gentle heating at
50°C.

2)

Further gelatin was precipitated out by adding 25 mL of acetone in one-shot.

3)

After two minutes, white-colored supernatant was discarded and gel-like
precipitate was redissolved in 25 mL o f distilled water by gentle heating at 50 °C.

4)

The solution was adjusted to pH 1.5 using 0.1 M hydrochloric acid.

5)

The clear solution was kept under stirring at 40 °C and 75 mL o f acetone was
slowly added at a rate o f 3 mL/minute

6)

Immediately after acetone addition, 0.4 mL of 25% glutaraldehyde was added and
stirred continuously for another one hour.

7)

The solution was incubated at room temperature overnight.

8)

The solution was washed three times using 75% acetone by centrifugation at
6,000-7,000 rpm for twenty minutes.
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